Advertisements


"Pharma Bro" Martin Shkreli banned from drug industry for life, ordered to pay nearly $65M

Martin Shkreli, the so-called “Pharma Bro” known for jacking up medicine prices, has been banned from the pharmaceutical industry for life and ordered to pay almost $65 million, according to New York’s top prosecutor......»»

Category: topSource: foxnewsJan 14th, 2022

United Airlines May Can Unvaccinated Workers, Even With Exemptions

United May Can Unvaccinated Workers, Even With Exemptions – Court; That, Plus Recent Supreme Court Actions, OKs Most Effective Vax Weapon [soros] Q3 2021 hedge fund letters, conferences and more United Airlines Can Put Unvaccinated Employees On Unpaid Leave A federal judge in Texas has held that United Airlines can put employees who have refused […] United May Can Unvaccinated Workers, Even With Exemptions – Court; That, Plus Recent Supreme Court Actions, OKs Most Effective Vax Weapon [soros] Q3 2021 hedge fund letters, conferences and more United Airlines Can Put Unvaccinated Employees On Unpaid Leave A federal judge in Texas has held that United Airlines can put employees who have refused to be vaccinated on unpaid leave, even if they have medical or religious exemptions. This, plus three recent strikes from the Supreme Court, mean that companies seem to have a green light to use the same technique which also proved so effective in fighting the earlier health crisis caused by smoking, says public interest law professor John Banzhaf, who says they should do so regarding of whether court action stays the federal OSHA mandatory vaccine policy for larger companies. The most recent Supreme Court ruling, refusing to block a requirement by Maine that its health care workers be vaccinated against Covid, was especially significant because the Maine rule did not permit exceptions for religious objections, and because it was rendered by the entire court. A similar request to stay a requirement by Indiana University that its students be vaccinated was turned down for the Court by Justice Amy Coney Barrett. But that university’s requirement permitted exceptions for religious, ethical and medical reasons; and they were virtually guaranteed to anyone who sought an exemption. Another legal strike against anti-vaxxers’ legal arguments occurred when the High Court refused to stop a vaccination requirement for virtually all personnel in New York City’s school system. A Green Light For Companies To Use The Same Tactics These three rulings – as well as earlier ones by lower courts and the new one in Texas – provide a green light for companies to use the same tactics which proved so effective in fighting a similar public health crisis, likewise fueled by a massive disinformation campaign, says Banzhaf, who established and then led the nonsmokers’ rights movement which got millions to quit and saved hundreds of billions of dollars. Using a stick is much more effective than a carrot in preventing unnecessary deaths and disabilities from smoking and also now also from Covid, says Banzhaf, who led the successful battle to save millions of smoker lives, and who has already begun contributing to saving lives threatened by Covid. Actually, says Banzhaf, “stick” is a misnomer since the measures proven to be so effective in getting smokers to quit, and now getting holdouts to be vaccinated, aren’t designed to punish their unhealthy conduct, but rather to prevent them from continuing to inflict the damage it causes on the majority in the form of risks to life and health, as well as in huge additional financial costs. It has long been known that warnings and other health messages – even when coupled with incentives such as medical assistance and financial rewards – were not very effective in getting smokers to quit; in part because they had to try to overcome a massive disinformation campaign by the tobacco industry. Bans On Smoking What was effective instead were restrictions and requirements – e.g., bans on smoking on airplanes, at public places, and in workplaces – says Banzhaf, who led the fight for smoking bans during flights and then elsewhere. The purpose was not to punish smokers (a stick) but rather to protect nonsmokers; but, by making it very inconvenient not to quit, many smokers yielded to that incentive, he says. He adds that when companies went further and started insisting on having a smoker-free work force, similar to a drug-free work force, compliance – despite some initial grumbling and treats of quitting – went even higher. In addition, by requiring smokers to bear more of the huge medical and other costs they had been imposing on others, the incentive to quit was substantially increased, and became even more effective. Banzhaf cites as examples the higher premiums he and the NAIC helped persuade health insurance companies to charge smokers, and especially the 50% smoker surcharge he helped to have included under Obamacare. The professor explains that the purpose of these financial moves once again was not so much to punish smokers or to pressure them to quit, but simply so that the huge costs they were imposing – estimated to be over $12,000/yr annually per smoker – would not be borne by nonsmokers in the form of higher taxes, lower workplace benefits, and ballooning health insurance premiums. Making Being Unvaccinated More Inconvenient And Expensive Now experience, backed up by research, is proving that the same strategy – making being unvaccinated more inconvenient and expensive – is, as with smoking, more effective than warnings and cajoling in getting people vaccinated. In other words, making employees and patrons at public venues provide proof of vaccination, requiring those who might be permitted to remain unvaccinated to pay for their own frequent Covid tests, charging higher health and other insurance rates for unvaccinated people (and also for any unvaccinated persons on their plans), and even declining to perform some medical operations on those refusing to be vaccinated, is the most effective way to fight Covid, and to protect the majority of Americans from infection, argues Banzhaf. Surveys suggest that these measures are also favored by a majority of Americans. Here are a few examples: A study in the Journal of the American Medical Association showed that lotteries to encourage vaccinations have little effect – “no statistically significant association” – in achieving that goal. In contrast, New York’s vaccination requirement get some 90% of its health care workers vaccinated. Indeed, the figures from even a month ago demonstrate the amazing effectiveness of New York’s requirement that health workers be vaccinated: Strong Memorial Hospital quickly achieved a 95.5% vaccination rate Albany Medical Center’s vaccination rate leaped to 98% St. Barnabas Hospital went from 20% unvaccinated to about 3% The Mohawk Valley Health System went up from 70% to about 96% Delta Airlines Achieved An Over 80% Compliance Rate United Airlines, one of the first big companies to require workers to be vaccinated or lose their jobs, found that, despite initial grumbling, about 99% of its employees agreed to be vaccinated. Similarly, Delta Airlines achieved an over 80% compliance rate by charging those who decline to be vaccinated a $200-per-month health insurance surcharge. Ochsner Health, the largest nonprofit health care system in Louisiana, now has the same surcharge. After Tyson Foods announced a vaccine requirement in early August, its vaccination rate jumped from 50% to at least 80%, even before the deadline for getting a shot. Novant Health in North Carolina, which originally announced that 375 of its 35,000 employees had been suspended and would soon be fired for being unvaccinated, found that 200 of the 375 finally did get vaccinated to keep their jobs, Despite a few widely reported situations where many employees threatened to quit – usually in situations where defiance was encouraged and led by recalcitrant unions – vaccine requirements have generally been very effective, are gaining in public support, have largely been upheld by the courts, and have lead to very few actual firings – the same results which occurred many years ago when companies first banned smoking on the job, and later even off the job. Making those who refuse to be vaccinated bear the consequences of their decisions – i.e., imposing some “personal responsibility” – has proven to be a very effective weapon in saving lives, and in helping to return life (especially life in the workplace and in many public places) to a near normal, with even less need if any for the vaccinated to be burdened with mask requirements, proclaims Banzhaf. Updated on Nov 9, 2021, 2:42 pm (function() { var sc = document.createElement("script"); sc.type = "text/javascript"; sc.async = true;sc.src = "//mixi.media/data/js/95481.js"; sc.charset = "utf-8";var s = document.getElementsByTagName("script")[0]; s.parentNode.insertBefore(sc, s); }()); window._F20 = window._F20 || []; _F20.push({container: 'F20WidgetContainer', placement: '', count: 3}); _F20.push({finish: true});.....»»

Category: blogSource: valuewalkNov 9th, 2021

Krysten Sinema is choosing lower taxes for the richest Americans over better healthcare for average Americans - and cutting the legs out from under the Build Back Better plan

In 2017, Kyrsten Sinema voted against Trump's agenda. Today, she's known as Big Pharma's favorite senator. Senator Kyrsten Sinema of Arizona. Tom Williams/CQ-Roll Call Inc. via Getty Images With the Build Back Better bill, Congress has the best opportunity to expand healthcare in America. Yet donations from Big Pharma have incentivized Senator Kyrsten Sinema to block reform. It's time to tax the rich and use those funds to expand healthcare access. Laura Packard is executive director of Health Care Voter, and founder of Health Care Voices. This is an opinion column. The thoughts expressed are those of the author. Four years ago I walked into a doctor's office as a successful and healthy self-employed woman. Or so I thought. I walked out with a stage 4 cancer diagnosis. I'm still here and in remission because of the care I received. I was lucky, because across America many people are still priced out of our healthcare system. As Congress advances the Build Back Better Act - a plan that would tackle many pressing issues in our society, including healthcare - they're also deciding what, and who, to leave out. And since Democrats are committed to making sure the plan doesn't add to the national debt, a lot of the decision making on what is in or out depends on how much money the bill can raise to offset the cost of the critical investments we need.Much depends on the votes of two Democratic senators: Kyrsten Sinema and Joe Manchin. They have both opposed various means of raising revenue by increasing taxes on the rich and corporations. Their stances make it harder to expand access to healthcare, so that no American has to choose between their finances and their life. Congressional allegiances should be with their constituents, not the giant pharmaceutical industry, big corporations, and the wealthy - and that means they should support raising taxes on the rich. The path ahead is clearIt's clear what the American people want: Polls show that eight in 10 American believe wealthy people and corporations aren't paying their fair share. At the same time, Americans want accessible and affordable healthcare and lower drug prices. The Build Back Better Act is the best way to achieve those goals: raise taxes and use that revenue to make Affordable Care Act plans more affordable, fill the Medicaid gap so low income Americans can get covered, and expand Medicare services to existing beneficiaries. At the same time, we can lower drug prices by giving Medicare the power to negotiate with pharmaceutical companies.Back when Sinema was a member of the House, she opposed Trump's 2017 tax cut, which slashed taxes for corporations and the richest households. Now, having since emerged as the "Pharma favorite" and raising more campaign money in the last three months than in any other quarter since she became a senator, Sinema is voicing staunch opposition to upping taxes for the ultra wealthy. In a 50-50 split Senate, Sinema's opposition is enough to force Democrats into dropping some of their most popular ideas. Speaking of the high costs of pharmaceutical drugs, while I was going through six months of chemotherapy, my insurance that I purchased through the Affordable Care Act picked up most of the tab. Cancer patients are incredibly vulnerable after treatment, because our immune systems have been knocked down to nothing. After my first chemotherapy session, my doctors prescribed a drug for me to help my immune system recover faster. The drug, Neulasta, is made by pharma giant Amgen and would have cost me over $13,000 per injection. My insurance didn't cover it, so I went without and hoped for the best. But I spiked a fever from infection, and wound up back in the hospital for a week. The high cost of prescription drugs nearly led to my death.We shouldn't have to live like this. Congress has an opportunity to lower the outrageous costs of medications and healthcare. Not only could a more robust BBB bill rein in these prices, but it could also force greedy corporations like Amgen - one of Sinema's top three campaign contributors - to pay their fair share of taxes too. Tap dancing around the taxmanIn 2018 Amgen saw its tax bill slashed by over $1.1 billion thanks to Trump's tax law, plus it snagged an additional estimated $5.5 billion of savings from a one-time tax break to incentivize corporations to repatriate untaxed offshore profits. Amgen used their gigantic tax cut for a $10 billion stock buyback, which just helped their CEO and wealthy shareholders get richer. And even with the cut, big corporations like Amgen don't pay even what they owe. In August of 2021, an IRS audit revealed that the company owed $3.6 billion in back taxes, which Amgen is disputing.I'm a small business owner, and I pay my taxes every quarter. Like many Americans, I often face a big bill each year on Tax Day. I don't have the benefit of fancy lawyers and lobbyists to avoid my responsibilities. It's time for big corporations and ultra-rich CEOs to pay up too. But Amgen and other big pharma companies have been pouring money into campaigns to make sure Sinema and other holdouts protect their interests, even if it's worse for most Americans.Amgen has spent $4.7 million, and PhRMA (the trade association for Big Pharma corporations) has racked up $15.2 million on lobbying this year alone. Pharmaceutical companies have spent the most of any industry on federal lobbying in 2021: They've showered Congress with $171 million so far, almost roughly twice the amount of the next highest-spending industry.PhRMA made a seven-figure ad buy to attack the lower prescription drug pricing proposals in Build Back Better, and, along with their allies, have also spent $18 million on ads opposing Medicare negotiation proposals for more affordable drugs.Unfortunately, their money is having an effect. The Build Back Better framework originally released by the White House didn't include pieces to lower drug prices. Taxes on billionaires' wealth, and higher tax rates on big corporations? Gone too. And because of the lack of revenue, Americans would be limited to a partial expansion of Medicare - just hearing services - and a time-limited version of ACA tax credits and filling the Medicaid gap, which expire after 2025.Thankfully, Sinema struck a deal with President Biden and Senate Majority Leader Chuck Schumer on drug pricing reform, agreeing to a plan that would allow Medicare to negotiate some medication costs and lower out-of-pocket costs for millions. It's now on the House and Senate to get the Build Back Better Act passed as quickly as possible, and for it to reach the president's desk without any further cuts or compromises.Taxing the rich and corporations continues to be very popular among Americans. Now we need elected officials to listen to people like you and me instead of their wealthy elite donors. The future of our healthcare depends on Congress' financial incentives to improve it, and that's a dangerous prescription for America.Read the original article on Business Insider.....»»

Category: topSource: businessinsiderNov 4th, 2021

How 1.5 million aloe vera leaves are harvested a week

Some aloe vera products don't contain any aloe. But at the world's largest aloe farm in the Dominican Republic, they're slicing up the legit stuff. Aloe vera products are growing in popularity, and the industry is now worth $625 million. But some aloe vera products have been found to contain no traces of aloe. We visited the world's largest aloe farm in the Dominican Republic to find out how they harvest, slice up, and juice the legit stuff. Following is a transcription of the video:Narrator: Making aloe products takes quick hands.Rudy Colón: The leaf has thorns. As it grows, it develops more thorns.Narrator: A good knife ...Ruben Martinez: Daily, each of the employees has to fillet about 3,000 to 3,500 leaves.Narrator: ... and lots of plants. It takes about 20 aloe leaves to make just one gallon of aloe vera juice. But some aloe products have been found to contain no aloe at all.Tod: It's so easy to put out a fake aloe product. So there are all kinds of synthetic gels.Narrator: So how are real aloe vera products made? And can we spot the legit stuff in a $625 million industry? We visited the largest aloe farm in the world to find out.Universal Aloe's farm covers 5,000 acres here in the Dominican Republic. While there are hundreds of types of aloe plants, this farm chose Aloe barbadensis Miller because it has 20 amino acids.Jason: Minerals, vitamins, carbohydrates, hormones, and other bioactive substances.Narrator: Once the baby plants are in the ground, it takes about eight months for them to mature. About 750 people harvest these fields. They're dispatched in groups, harvesting section by section.Rudy: You always remove the leaf that is full and cut and remove the tip. Then you remove the thorns at the bottom. We cut the mature leaf, going leaf by leaf not to hurt the plant that is going to remain.Narrator: The cut leaves won't grow back, but the plants will grow new ones. It will take them about a week to harvest just this one area.Rudy: The sun hits very hard here. And that's the tough thing about this job, but we are used to it. We need to work.Narrator: One by one, workers pick up all the harvested leaves and toss them into a truck. Those leaves head to a processing plant 2 miles up the road.Leonel Mesa: Every day, we get 260,000 pounds of fresh leaves here. And that's converted into 20,000 gallons of fresh juice for export daily. The process starts with the washing and disinfecting of the leaves.Narrator: The leaves go through a bath of chlorinated saltwater to kill off any little critters from the field that may be hanging around. Then they get trimmed.Leonel: They remove both the head and the tail of the leaf so that it is easier to extract the gel in the extraction area. And then we wash them a second time.Narrator: This jiggly fillet is the gel inside the aloe leaf. That's what's used in real aloe vera juice, gel, or skincare products.Leonel: We manually fillet the aloe vera leaves to remove the gel.Narrator: To do it, They need a really good knife.Ruben: I call him Lightning, because when I put him in, I feel like I'm going fast with him. It practically does the work for me.Narrator: They might make it look easy, but filleting takes precision.Ruben: It has to be placed exactly on the right spot to get the gel out of the leaf. It varies according to what sizes the leaves come in. When the leaves are bigger, it's good, because we are more productive. But when we get small leaves, it takes us longer to fillet them, and we get tired. We want to stop working.Narrator: And they have to move fast, filleting 3,500 leaves a day.Ruben: The fastest filleter? There are a lot. Sometimes we start to hold competitions to see who is faster. To sum it up, we are good.Narrator: Many aloe companies use machines for filleting.Leonel: Our production process is very artisanal. Around 80% of our entire process is manual because it produces less waste and because the leaves come in very different sizes.Narrator: The leftover leaf bits go back out into the field as compost. And the buckets of filets? Those get weighed, then poured onto this big table. Workers here will inspect them for any leftover leaf bits, which they'll then slice off. Once it's all clear, the fillets head to the shredder, which grinds them into a pure aloe gel.Leonel: From here, they pass to these pasteurization tubes. Any type of impurities and bacteria that could have been in the juice are removed.Narrator: At this point, ascorbic acid is added to extend the shelf life.Leonel: Our product is 99.9% pure aloe vera, and the other 0.1% is ascorbic acid.Narrator: The gel flows into this spill-proof bag.Leonel: These two robotic devices take the lid off the metallic bag, open it, fill it up, and seal it automatically so that there is no contact with the exterior.Narrator: This bag is then vacuum-sealed and put into a bigger metal box. The whole process from leaf to this container takes only about three hours. But before the shipment can leave the factory, its contents have to be tested for quality assurance.Leonel: We take about 20 to 25 samples daily.Jesus Santiago Jaquez: The chemical-physical test analyzes the pH, the viscosity, the color, texture, and everything concerning the appearance of the juice.Rafaelina Taveras: It takes me about an hour to do this kind of test.Narrator: Only when a container passes the lab tests can it be released for shipment. These ones are bound for Rotterdam in the Netherlands. There, the gel will be pumped into bottles for Forever Living products. But not every bottle of aloe is made like this. In 2015, ConsumerLab.com tested 10 aloe products for ingredients.Tod: Half of them failed our test.Narrator: A 2016 Bloomberg investigation found that Walmart, CVS, and Target's aloe products contain no evidence of aloe at all.Tod: It's so easy to put out a fake aloe product. So there are all kinds of synthetic gels. Often you'll see a word like carbomer. It's a synthetic gel. And if you see a clear gel, you have no idea if it's really aloe or carbomer.Narrator: Most aloe products aren't closely regulated by the FDA. That's because they're considered supplements, or cosmetics, not drugs. So a product can say it contains aloe, but it could mean a range of things: It really does contain aloe fillet, or it's the whole leaf ground up and not just that inner fillet. Or it's a synthetic gel, and there's actually no aloe - which won't hurt you, but doesn't have any of the supposed benefits of aloe.Tod: There's not a lot of regulation or oversight of aloe products.Narrator: It's also hard to regulate because aloe grows naturally all over the Americas, and its gel has been used for thousands of years to heal burns and reduce inflammation.Jason: The challenge is translating that history to our current rigorous medical examination.Narrator: Another problem is there isn't clear scientific proof of aloe's healing powers. Some studies have shown it helps soothe burns and speed up healing, while others show no effect on burns.Tod: So it's not that aloe doesn't help. The evidence isn't there right now.Narrator: The outer rind of the leaf has been found to have a laxative compound called aloin. One study found that it caused cancer in rats, while another found it helped with constipation. But the FDA has banned aloe from being sold as an over-the-counter laxative drug.Tod: There's no patent on aloe, and so there isn't a lot of incentive for companies to be putting lots of money into clinical studies. They don't really need to do those studies to get these products on the shelf.Narrator: Still, consumers worldwide are flocking to aloe as they embrace more natural products. Universal Aloe saw a 30% increase in demand in 2020. As consumers navigate this growing market, how can we identify the products made with real aloe vera? Well, Todd says it's actually really tricky, but he did have a few suggestions. First, you should always check the ingredient list.Tod: You want to see aloe. You want to see it's first. You really need to be super careful on the wording, because if it just says "leaf," it could be any part of the leaf. You could be getting the latex, which you don't want, unless you want a laxative effect.Narrator: Look out for tricky wording like "100% gel." That could mean there is 100% gel, but not all of it is aloe fillet.Jason: So you really need to know what part of the leaf is being made. When they "aloe gel," is it a gel that's made from blending up the whole leaf, or is it truly just pure aloe gel?Narrator: Despite these uncertainties, experts don't expect the demand for aloe to dip anytime soon.Read the original article on Business Insider.....»»

Category: topSource: businessinsiderNov 2nd, 2021

Stick Better Than Carrot For Saving Lives – With Both Covid And Smoking

Stick Better Than Carrot For Saving Lives – With Both Covid And Smoking; Appeals Only Marginally Effective Against Massive Disinformation Campaigns Q3 2021 hedge fund letters, conferences and more Using A Stick Is Much More Effective Than A Carrot WASHINGTON, D.C. (October 26, 2021) – Using a stick is much more effective than a carrot […] Stick Better Than Carrot For Saving Lives – With Both Covid And Smoking; Appeals Only Marginally Effective Against Massive Disinformation Campaigns if (typeof jQuery == 'undefined') { document.write(''); } .first{clear:both;margin-left:0}.one-third{width:31.034482758621%;float:left;margin-left:3.448275862069%}.two-thirds{width:65.51724137931%;float:left}form.ebook-styles .af-element input{border:0;border-radius:0;padding:8px}form.ebook-styles .af-element{width:220px;float:left}form.ebook-styles .af-element.buttonContainer{width:115px;float:left;margin-left: 6px;}form.ebook-styles .af-element.buttonContainer input.submit{width:115px;padding:10px 6px 8px;text-transform:uppercase;border-radius:0;border:0;font-size:15px}form.ebook-styles .af-body.af-standards input.submit{width:115px}form.ebook-styles .af-element.privacyPolicy{width:100%;font-size:12px;margin:10px auto 0}form.ebook-styles .af-element.privacyPolicy p{font-size:11px;margin-bottom:0}form.ebook-styles .af-body input.text{height:40px;padding:2px 10px !important} form.ebook-styles .error, form.ebook-styles #error { color:#d00; } form.ebook-styles .formfields h1, form.ebook-styles .formfields #mg-logo, form.ebook-styles .formfields #mg-footer { display: none; } form.ebook-styles .formfields { font-size: 12px; } form.ebook-styles .formfields p { margin: 4px 0; } Get The Full Walter Schloss Series in PDF Get the entire 10-part series on Walter Schloss in PDF. Save it to your desktop, read it on your tablet, or email to your colleagues. (function($) {window.fnames = new Array(); window.ftypes = new Array();fnames[0]='EMAIL';ftypes[0]='email';}(jQuery));var $mcj = jQuery.noConflict(true); Q3 2021 hedge fund letters, conferences and more Using A Stick Is Much More Effective Than A Carrot WASHINGTON, D.C. (October 26, 2021) - Using a stick is much more effective than a carrot in preventing unnecessary deaths and disabilities from smoking and also now also from Covid, says public interest law professor John Banzhaf, who led the successful battle to save millions of smoker lives, and who has already begun contributing to saving lives threatened by Covid. Actually, says Banzhaf, "stick" is a misnomer since the measures proven to be so effective in getting smokers to quit, and now holdouts to be vaccinated, aren't designed to punish their unhealthy conduct, but rather to prevent them from continuing to inflict the damage it causes on the majority in the form of risks to life and health, as well as in huge additional financial costs. It has long been known that warnings and other health messages - even when coupled with incentives such as medical assistance and financial rewards - were not very effective in getting smokers to quit; in part because they had to try to overcome a massive disinformation campaign by the tobacco industry. What was effective were restrictions and requirements - e.g., bans on smoking on airplanes, at public places, and in workplaces - says Banzhaf, who led the fight for smoking bans during flights and then elsewhere. The purpose was not to punish smokers (a stick) but rather to protect nonsmokers; but, by making it very inconvenient not to quit, many smokers yielded to that incentive, he says. He adds that when companies went further and started insisting on having a smoker-free work force, similar to a drug-free work force, compliance - despite some initial grumbling and treats of quitting - went even higher. The Incentive To Quit Smoking In addition, by requiring smokers to bear more of the huge medical and other costs they had been imposing on others, the incentive to quit was substantially increased, and became even more effective. Banzhaf cites as examples the higher premiums he and the NAIC helped persuade health insurance to charge smokers, and especially the 50% smoker surcharge he helped promote under Obamacare. The professor explains that the purpose of these financial moves once again was not so much to punish smokers or to pressure them to quit, but simply so that the huge costs they were imposing - estimated to be over $12,000/yr annually per smoker - would not be borne by nonsmokers in the form of higher taxes, lower workplace benefits, and ballooning health insurance premiums. Now experience, backed up by research, is proving that the same strategy - making being unvaccinated more inconvenient and expensive - is, as with smoking, more effective than warnings and cajoling in getting people vaccinated. Proof Of Covid Vaccination In other words, making employees and patrons at public venues provide proof of vaccination, requiring those who might be permitted to remain unvaccinated to pay for their own frequent Covid tests, charging higher health and other insurance rates for unvaccinated people (and also for any unvaccinated persons on their plans), and even declining to perform some medical operations on those refusing to be vaccinated, is the most effective way to fight Covid, and to protect the majority of Americans from infection, argues Banzhaf. Here are a few examples: A study in the Journal of the American Medical Association showed that lotteries to encourage vaccinations have little effect - “no statistically significant association” - in achieving that goal. In contrast, New York's vaccination requirement get some 90% of its health care workers vaccinated. Indeed, the figures from even a month ago demonstrate the amazing effectiveness of New York's requirement that health workers be vaccinated: Strong Memorial Hospital quickly achieved a 95.5% vaccination rate Albany Medical Center's vaccination rate leaped to 98% St. Barnabas Hospital went from 20% unvaccinated to about 3% The Mohawk Valley Health System went up from 70% to about 96% Vaccination Requirements United Airlines, one of the first big companies to require workers to be vaccinated or lose their jobs, found that, despite initial grumbling, about 99% of its employees agreed to be vaccinated. Similarly, Delta Airlines achieved an over 80% compliance rate by charging those who decline to be vaccinated a $200-per-month health insurance surcharge. Ochsner Health, the largest nonprofit health care system in Louisiana, now has the same surcharge. After Tyson Foods announced a vaccine requirement in early August, its vaccination rate jumped from 50% to at least 80%, even before the deadline for getting a shot. Novant Health in North Carolina, which originally announced that 375 of its 35,000 employees had been suspended and would soon be fired for being unvaccinated, found that 200 of the 375 finally did get vaccinated to keep their jobs, Despite a few widely reported situations where many employees threatened to quit - usually in situations where defiance was encouraged and led by recalcitrant unions - vaccine requirements have generally been very effective, are gaining in public support, have largely been upheld by the courts, and have lead to very few actual firings - the same results which occurred many years ago when companies first banned smoking on the job, and later even off the job. Making those who refuse to be vaccinated bear the consequences of their decisions - i.e., imposing some "personal responsibility" - has proven to be a very effective weapon in saving lives, and in helping to return life (especially life in the workplace and in many public places) to a near normal, with even less need for the vaccinated to be burdened with mask requirements, proclaims Banzhaf. Updated on Oct 26, 2021, 2:56 pm (function() { var sc = document.createElement("script"); sc.type = "text/javascript"; sc.async = true;sc.src = "//mixi.media/data/js/95481.js"; sc.charset = "utf-8";var s = document.getElementsByTagName("script")[0]; s.parentNode.insertBefore(sc, s); }()); window._F20 = window._F20 || []; _F20.push({container: 'F20WidgetContainer', placement: '', count: 3}); _F20.push({finish: true});.....»»

Category: blogSource: valuewalkOct 26th, 2021

Some Americans were primed for vaccine skepticism after decades of mistrust in Big Pharma

Now, vaccine makers have made billions selling COVID-19 shots to countries, and soaring pharma stocks have minted a class of "vaccine billionaires." How distrust in pharmaceutical firms gave rise to the anti-vaxx movement, according to experts in the anti-vaccine movement and the history of Big Pharma. Samantha Lee/Insider Claims of mismanagement and greed in the pharmaceutical industry may have contributed to vaccine hesitancy. Of Americans who said they would "definitely not" get a COVID-19 vaccine, 20% say they trust drug companies, according to KFF. Pharma companies are now lobbying against waiving intellectual property protections for COVID-19 vaccines. Ten months after the world's first COVID-19 vaccine received an emergency green light for use, the US is still reeling from COVID cases among mostly unvaccinated Americans.Among Americans who said in a recent survey that they will "definitely not" get a COVID-19 vaccine, only 20% said they trust pharmaceutical companies to provide reliable information, according to Ashley Kirzinger, the associate director of public opinion and survey research at the Kaiser Family Foundation.Pharmaceutical companies large and small are responsible for advancements in medical treatments that have helped cure diseases, relieve chronic pain, and save lives. Several developed COVID-19 vaccines that are highly effective at preventing severe disease. But publicized claims of mismanagement and greed among some of the world's largest pharmaceutical companies, collectively known as Big Pharma, have eroded public trust and, in turn, have contributed to vaccine hesitancy among some Americans, experts told Insider."In the '50s, after World War II, the drug industry was highly respected; they saved hundreds of thousands of lives," Gerald Posner, investigative journalist and the author of "Pharma: Greed, Lies, and the Poisoning of America," said in an interview. "They lost that over decades of greed and mismanagement."Now, as some pharmaceutical companies lobby to keep their COVID-19 vaccine formulas out of the hands of manufacturers in low-income countries (thereby maximizing profits from the life-saving shot), some Americans may develop a renewed distrust of Big Pharma, Posner said."[Pharmaceutical companies] are behaving as if they have absolutely no responsibility beyond maximizing the return on investment," Tom Frieden, infectious disease expert and a former head of the Centers for Disease Control and Prevention, told The New York Times.Skepticism of Big Pharma has been decades in the makingAmerican trust in Big Pharma reached a peak in the early-to-mid 20th century, when the pharmaceutical industry ushered in life-saving treatments like penicillin and vaccines, as Patrick Radden Keefe reports in his book "Empire of Pain."Public trust started to erode, however, with the invention and widespread adoption of addictive drugs, Keefe reported. Gallup, whose polling has placed pharmaceutical companies as America's least liked industry for the past two decades, attributes the public's dislike to the companies' high drug prices, tremendous lobbying budgets, and their roles in the opioid epidemic.Over the last 50 years, lawsuits began piling up against pharmaceutical companies, including those that developed COVID-19 vaccines. In 2013, Johnson & Johnson settled a federal investigation involving marketing fraud of several drugs, including one to treat dementia patients. Reuters reported in 2018 that small amounts of asbestos were found in the company's baby powder between the early 1970s and the early 2000s. The report claimed that the company failed to disclose that information, which Johnson & Johnson has repeatedly denied. The company is facing thousands of lawsuits alleging that the talc-based products caused cancer and mesothelioma.Last year, 46 US states sued 26 drug makers, including Pfizer, over allegations of conspiring to drive up drug prices. (Pfizer told Reuters the company did not behave in unlawful conduct.)In 2009, Pfizer, which produced the first FDA-approved COVID-19 vaccine, paid the second-largest healthcare fraud settlement in US history to settle accusations of misleading advertising of an anti-inflammatory drug. When asked to comment on this article, a Pfizer spokesperson told Insider the company "cannot speculate why some remain vaccine hesitant, but vaccination remains one of the best tools we have to help protect lives and work to achieve herd immunity."The anti-vaccine movement in the US, which gained momentum in the early 2000s, has tried to use drug industry scandals to discourage parents from inoculating their children, according to Dr. Stewart Lyman, the owner of Lyman Biopharma Consulting LLC and a vaccine advocate.In the mid-2010s, measles in children began resurfacing despite the CDC having declared measles as eliminated from the US in 2000. Some anti-vaccine believers fought for personal exemptions for vaccine mandates during local measles outbreaks. Others within the movement said not to trust the pharmaceutical company Merck with vaccines because of a whistleblower complaint claiming that the company overstated the effectiveness of the shot. (Merck did not respond to Insider's request for comment.) "In the fifties, after World War II, the drug industry was highly respected; they saved hundreds of thousands of lives," Gerald Posner, and investigative journalist and the author of "Pharma: Greed, Lies, and the Poisoning of America, said in an interview. "They lost that over decades of greed and mismanagement." Erik McGregor/LightRocket via Getty Images Big Pharma's business model drives mistrust among vaccine skepticsKirzinger told Insider anecdotal data from Kaiser suggests some Americans are hesitant about the COVID-19 vaccine due to how pharmaceutical industries profit from shots, despite the shots being rigorously tested by scientists before given to the public and built on decades of research. Vaccine makers have made billions in revenue by selling the shots to countries, and soaring pharmaceutical stocks have minted a class of "vaccine billionaires.""[Some vaccine hesitant Americans] are talking about distrust of Pharma because they think that they're mostly concerned about profits rather than safety," Kirzinger said.The price of the life-saving hormone insulin, for example, has skyrocketed in the last decade, costing diabetes patients around $300 for a 10-millimeter vial, up from about $93 in 2009. Many low-income Americans have resorted to rationing insulin to make it last longer, and lawmakers are pressuring drug companies to reduce costs.Still, pharma companies are currently lobbying President Joe Biden to prevent him from waiving intellectual property protections for COVID-19 vaccines - thereby keeping manufacturers in poor countries from making life-saving shots for vulnerable populations.And while some vaccine makers like Johnson & Johnson have sold COVID-19 vaccines at cost, others, including Pfizer and Moderna, have sold them for a profit.Read the original article on Business Insider.....»»

Category: topSource: businessinsiderOct 24th, 2021

Roche"s (RHHBY) AD Drug Gets Breakthrough Therapy Status

Roche (RHHBY) gets Breakthrough Therapy Designation for gantenerumab for Alzheime's disease, which puts the spotlight on this challenging but promising space. Roche RHHBY recently announced that the FDA has granted a Breakthrough Therapy Designation to its pipeline candidate, gantenerumab for the treatment of people with Alzheimer’s disease (AD).This designation accelerates the development and review of drugs and treatments that are intended to treat serious or life-threatening conditions with preliminary evidence indicating that they may demonstrate a substantial improvement over available therapies having full FDA approval.Gantenerumab is an anti-amyloid beta antibody developed for subcutaneous administration.  The designation was based on data that showed gantenerumab significantly reduced brain amyloid plaque, a pathological hallmark of AD, in the ongoing SCarlet RoAD and Marguerite RoAD open-label extension studies, as well as other studies.The data observed from these studies have been incorporated into the optimized design of two ongoing parallel, global, placebo-controlled and randomized phase III studies — GRADUATE 1 and 2. The studies are evaluating gantenerumab in more than 2,000 participants for more than two years and are expected to be completed in the second half of 2022.Spotlight on AD TreatmentsThe FDA approval of Biogen’s BIIB and Eisai’s AD drug, Aduhelm (aducanumab), in June 2021 has put the spotlight on AD treatments. AD is a progressive, fatal disease of the brain, which is characterized by a decline in memory, language and other thinking skills along with behavioral changes. AD is the most common form of dementia. Approximately 10 million people globally are diagnosed with AD each year.However, Biogen recently mentioned that the launch of Aduhelm is facing some near-term launch challenges. Given the rising cases and lack of treatments, quite a few companies have invested millions and billions of dollars to successfully develop a treatment for the same but most have failed.Nevertheless, most of the bigwigs and smaller pharma/bioetechs continue to develop treatments for this promising yet challenging space. Biogen and partner Eisai recently announced that the latter has initiated a rolling submission of a biologics license application (BLA) for pipeline candidate, lecanemab (BAN2401).  The BLA is seeking approval for the candidate as a treatment for early AD under an accelerated pathway in the United States.Let us take a look at some of the other companies which have promising candidates in the pipeline for AD:3 Companies With Promising AD CandidatesProthena Corporation PRTA has a portfolio of programs for the potential treatment of AD including PRX012, which targets Aβ (Amyloid beta) and a novel dual Aβ-Tau vaccine. PRX012 is a high-affinity monoclonal antibody targeting a key epitope within the N-terminus of Aβ. The company is developing PRX012 as a next-generation, high potency, anti-abeta antibody with best-in-class potential. Another promising candidate is PRX005. It is an investigational antibody that targets tau, a protein implicated in diseases including AD. Prothena is developing a dual vaccine, which concomitantly targets key epitopes within both the Aβ and tau proteins. The dual Aβ-Tau vaccine is being developed for the potential prevention and treatment of Alzheimer’s disease.    Cassava Sciences, Inc. SAVA is evaluating its pipeline candidate simufilam, a proprietary, small molecule (oral) drug that restores the normal shape and function of altered filamin A (FLNA) protein in the brain, for AD. The company recently initiated an initial phase III efficacy study of simufilam. A second phase III efficacy study of simufilam in AD is expected to begin by the year-end. The late-stage efficacy studies of simufilam in AD are being conducted under Special Protocol Assessments (SPA) from the FDA.Eli Lilly and Company LLY is evaluating donanemab, an investigational antibody therapy for AD. The company's phase II study, TRAILBLAZER-ALZ, investigated the efficacy and safety of donanemab in patients with early, symptomatic AD.  Lilly intends to submit a BLA for donanemab under the accelerated approval pathway later this year based on data from TRAILBLAZER-ALZ. The safety, tolerability and efficacy of donanemab are also being evaluated in the ongoing phase III study TRAILBLAZER-ALZ 2  Time to Invest in Legal Marijuana If you’re looking for big gains, there couldn’t be a better time to get in on a young industry primed to skyrocket from $17.7 billion back in 2019 to an expected $73.6 billion by 2027. After a clean sweep of 6 election referendums in 5 states, pot is now legal in 36 states plus D.C. Federal legalization is expected soon and that could be a still greater bonanza for investors. Even before the latest wave of legalization, Zacks Investment Research has recommended pot stocks that have shot up as high as +285.9%. You’re invited to check out Zacks’ Marijuana Moneymakers: An Investor’s Guide. It features a timely Watch List of pot stocks and ETFs with exceptional growth potential.Today, Download Marijuana Moneymakers FREE >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Biogen Inc. (BIIB): Free Stock Analysis Report Roche Holding AG (RHHBY): Free Stock Analysis Report Eli Lilly and Company (LLY): Free Stock Analysis Report Prothena Corporation plc (PRTA): Free Stock Analysis Report Cassava Sciences, Inc. (SAVA): Free Stock Analysis Report To read this article on Zacks.com click here......»»

Category: topSource: zacksOct 12th, 2021

3 Small Biotech Stocks in Focus on World Arthritis Day

Here we discuss three drugs or biotech companies with promising candidates in their pipeline for Arthritis indications. Every year World Arthritis Day is observed on Oct 12 to raise awareness on the disease’s far-reaching impact on patients across the globe. On this day, several arthritis-related groups including the Arthritis Foundation and European Alliance of Associations for Rheumatology (“EULAR”) spread messages on how to prevent arthritis and adopt healthy living.Although arthritis is not life threatening, it severely impacts the quality of life and participation in society of people suffering from the disease. The disease impacts a person’s self-esteem and also increases the burden on the state given their inability to work.Arthritis causes pain, swelling and stiffness in joints. There are several factors that may lead to arthritis including normal wear and tear in the body and inheritance. It is estimated that more than 54 million or approximately 23% of the U.S. adult population suffers from this ailment. Among them, 24 million adult patients face some type of limitations in their day-to-day life activities. Moreover, about a quarter of the adults suffering from arthritis suffer from severe joint pain. Arthritis commonly affects people who are already suffering from chronic diseases including diabetes, heart disease, and obesity, which may lead to failure of proper management of the diseases.We note that osteoarthritis (“OA”) is the most common form of arthritis, which occurs mainly due to normal wear and tear in the body and the risk increases with age. The other types of arthritis also known as inflammatory arthritis include gout, rheumatoid arthritis (“RA”), and lupus. Inflammatory arthritis occurs when the body’s immune system mistakenly attacks healthy tissues. When a person is diagnosed with arthritis before the age of 16, the condition is known as juvenile idiopathic arthritis.Drugs/Therapies Currently ApprovedWith several different types of arthritis, the treatment options also vary for each type. Currently, there is no cure for the disease and the treatment options either manage the symptoms or slow down the disease progression. It is believed that earlier a treatment is started, the better it is for the patients to help them manage the disease efficiently. However, arthritis is majorly diagnosed at a later stage that makes management of the disease difficult.The treatment options available for OA include primarily painkillers or non-steroidal anti-inflammatory drugs. Surgery or joint replacements are available options for severe OA patients who do not get any relief with other treatment options. Although OA affects nearly 60% of the U.S. adult population suffering from arthritis, there have been no major developments in the treatment of this debilitating disease. However, inflammatory arthritis has several treatment options with different mechanisms, which help to manage disease progression. Some popular drugs available to treat rheumatoid arthritis include Abbvie’s ABBV Humira, Amgen’s AMGN Enbrel and J&J’s JNJ Remicade. There are several types of therapies available to treat lupus as well. Pfizer’s Xeljanz and Abbvie’s Rinvoq are two of the several drugs available for treating juvenile idiopathic arthritis. Several other big pharma companies market drugs targeting arthritis indications, making it a highly competitive field. However, with a rise in the aging population, the demand for arthritis drugs is likely to increase going forward.Stocks in FocusHere we present three small biotech/drug stocks with promising and innovative pipeline candidates targeting a type of arthritis. Successful development of these candidates will drive the prospects of the companies going forward.Bioventus BVSIt is one of the leading companies in the osteoarthritis segment with a market-leading portfolio of hyaluronic acid-based therapies used to treat knee pain due to OA. Currently, the company is evaluating a placental tissue particulate candidate, PTP-001, as a potential treatment for OA of the knee in a phase I study. With its significant presence in the OA segment, the company is likely to gain significantly from robust growth of the market, if it can successfully develop a cure. Moreover, positive updates on the candidate will likely drive shares higher.IMab IMABThe company is developing a pipeline candidate, plonmarlimab, as a potential treatment for RA in a phase I study. The disease-modifying anti-rheumatic candidate has the potential to be developed for treating other autoimmune and inflammatory indications. There is a significant unmet need for RA patients. The successful development of plonmarlimab is likely to boost the company’s prospects. Moreover, the company is also developing several other pipeline candidates targeting different diseases including several attractive oncology indications.Alpine Immune Sciences ALPNThe company is developing its pipeline candidate, ALPN-101, for treating patients with systemic lupus erythematosus in a phase II study. The company is developing the candidate in collaboration with AbbVie. A strong partner should help the company ward off any financial hurdle. Moreover, the company has a promising checkpoint inhibitor candidate, ALPN-202 that is being developed in combination with Merck’s anti PD-1 therapy, Keytruda, for treating advanced malignancies in an early-stage study. Time to Invest in Legal Marijuana If you’re looking for big gains, there couldn’t be a better time to get in on a young industry primed to skyrocket from $17.7 billion back in 2019 to an expected $73.6 billion by 2027. After a clean sweep of 6 election referendums in 5 states, pot is now legal in 36 states plus D.C. Federal legalization is expected soon and that could be a still greater bonanza for investors. Even before the latest wave of legalization, Zacks Investment Research has recommended pot stocks that have shot up as high as +285.9%. You’re invited to check out Zacks’ Marijuana Moneymakers: An Investor’s Guide. It features a timely Watch List of pot stocks and ETFs with exceptional growth potential.Today, Download Marijuana Moneymakers FREE >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Johnson & Johnson (JNJ): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Alpine Immune Sciences, Inc. (ALPN): Free Stock Analysis Report IMab Sponsored ADR (IMAB): Free Stock Analysis Report Bioventus Inc. (BVS): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research.....»»

Category: topSource: zacksOct 12th, 2021

Snowden: Your Money AND Your Life

Snowden: Your Money AND Your Life Submitted by Edward Snowden via Continuing Ed, 1. This week's news, or “news,” about the US Treasury’s ability, or willingness, or just trial-balloon troll-suggestion to mint a one trillion dollar ($1,000,000,000,000) platinum coin in order to extend the country’s debt-limit reminded me of some other monetary reading I encountered, during the sweltering summer, when it first became clear to many that the greatest impediment to any new American infrastructure bill wasn’t going to be the debt-ceiling but the Congressional floor. That reading, which I accomplished while preparing lunch with the help of my favorite infrastructure, namely electricity, was of a transcript of a speech given by one Christopher J. Waller, a freshly-minted governor of the United States’ 51st and most powerful state, the Federal Reserve. The subject of this speech? CBDCs—which aren’t, unfortunately, some new form of cannabinoid that you might’ve missed, but instead the acronym for Central Bank Digital Currencies—the newest danger cresting the public horizon. Now, before we go any further, let me say that it’s been difficult for me to decide what exactly this speech is—whether it’s a minority report or just an attempt to pander to his hosts, the American Enterprise Institute.  But given that Waller, an economist and a last-minute Trump appointee to the Fed, will serve his term until January 2030, we lunchtime readers might discern an effort to influence future policy, and specifically to influence the Fed’s much-heralded and still-forthcoming “discussion paper”—a group-authored text—on the topic of the costs and benefits of creating a CBDC. That is, on the costs and benefits of creating an American CBDC, because China has already announced one, as have about a dozen other countries including most recently Nigeria, which in early October will roll out the eNaira. By this point, a reader who isn’t yet a subscriber to this particular Substack might be asking themselves, what the hell is a Central Bank Digital Currency?  Reader, I will tell you. Rather, I will tell you what a CBDC is NOT—it is NOT, as Wikipedia might tell you, a digital dollar. After all, most dollars are already digital, existing not as something folded in your wallet, but as an entry in a bank’s database, faithfully requested and rendered beneath the glass of your phone. In every example, money cannot exist outside the knowledge of the Central Bank Neither is a Central Bank Digital Currency a State-level embrace of cryptocurrency—at least not of cryptocurrency as pretty much everyone in the world who uses it currently understands it. Instead, a CBDC is something closer to being a perversion of cryptocurrency, or at least of the founding principles and protocols of cryptocurrency—a cryptofascist currency, an evil twin entered into the ledgers on Opposite Day, expressly designed to deny its users the basic ownership of their money and to install the State at the mediating center of every transaction.  2. For thousands of years priors to the advent of CBDCs, money—the conceptual unit of account that we represent with the generally physical, tangible objects we call currency—has been chiefly embodied in the form of coins struck from precious metals. The adjective “precious”—referring to the fundamental limit on availability established by what a massive pain in the ass it was to find and dig up the intrinsically scarce commodity out of the ground—was important, because, well, everyone cheats: the buyer in the marketplace shaves down his metal coin and saves up the scraps, the seller in the marketplace weighs the metal coin on dishonest scales, and the minter of the coin, who is usually the regent, or the State, dilutes the preciosity of the coin’s metal with lesser materials, to say nothing of other methods. Behold the glory of thelaw The history of banking is in many ways the history of this dilution—as governments soon discovered that through mere legislation they could declare that everyone within their borders had to accept that this year’s coins were equal to last year’s coins, even if the new coins had less silver and more lead. In many countries, the penalties for casting doubt on this system, even for pointing out the adulteration, was asset-seizure at best, and at worst: hanging, beheading, death-by-fire. In Imperial Rome, this currency-degradation, which today might be described as a “financial innovation,” would go on to finance previously-unaffordable policies and forever wars, leading eventually to the Crisis of the Third Century and Diocletian’s Edict on Maximum Prices, which outlived the collapse of the Roman economy and the empire itself in an appropriately memorable way: Tired of carrying around weighty bags of dinar and denarii, post-third-century merchants, particularly post-third-century traveling merchants, created more symbolic forms of currency, and so created commercial banking—the populist version of royal treasuries—whose most important early instruments were institutional promissory notes, which didn’t have their own intrinsic value but were backed by a commodity: They were pieces of parchment and paper that represented the right to be exchanged for some amount of a more-or-less intrinsically valuable coinage. The regimes that emerged from the fires of Rome extended this concept to establish their own convertible currencies, and little tiny shreds of rag circulated within the economy alongside their identical-in-symbolic-value, but distinct-in-intrinsic-value, coin equivalents. Beginning with an increase in printing paper notes, continuing with the cancellation of the right to exchange them for coinage, and culminating in the zinc-and-copper debasement of the coinage itself, city-states and later enterprising nation-states finally achieved what our old friend Waller and his cronies at the Fed would generously describe as “sovereign currency:” a handsome napkin. Sovereign currency, as known to history Once currency is understood in this way, it’s a short hop from napkin to network. The principle is the same: the new digital token circulates alongside the increasingly-absent old physical token. At first. Just as America’s old paper Silver Certificate could once be exchanged for a shiny, one-ounce Silver Dollar, the balance of digital dollars displayed on your phone banking app can today still be redeemed at a commercial bank for one printed green napkin, so long as that bank remains solvent or retains its depository insurance.  Should that promise-of-redemption seem a cold comfort, you’d do well to remember that the napkin in your wallet is still better than what you traded it for: a mere claim on a napkin for your wallet. Also, once that napkin is securely stowed away in your purse—or murse—the bank no longer gets to decide, or even know, how and where you use it. Also, the napkin will still work when the power-grid fails. The perfect companion for any reader’s lunch. 3. Advocates of CBDCs contend that these strictly-centralized currencies are the realization of a bold new standard—not a Gold Standard, or a Silver Standard, or even a Blockchain Standard, but something like a Spreadsheet Standard, where every central-bank-issued-dollar is held by a central-bank-managed account, recorded in a vast ledger-of-State that can be continuously scrutizined and eternally revised. CBDC proponents claim that this will make everyday transactions both safer (by removing counterparty risk), and easier to tax (by rendering it well nigh impossible to hide money from the government).  CBDC opponents, however, cite that very same purported “safety” and “ease” to argue that an e-dollar, say, is merely an extension to, or financial manifestation of, the ever-encroaching surveillance state. To these critics, the method by which this proposal eradicates bankruptcy fallout and tax dodgers draws a bright red line under its deadly flaw: these only come at the cost of placing the State, newly privy to the use and custodianship of every dollar, at the center of monetary interaction. Look at China, the napkin-clingers cry, where the new ban on Bitcoin, along with the release of the digital-yuan, is clearly intended to increase the ability of the State to “intermediate”—to impose itself in the middle of—every last transaction. “Intermediation,” and its opposite “disintermediation,” constitute the heart of the matter, and it’s notable how reliant Waller’s speech is on these terms, whose origins can be found not in capitalist policy but, ironically, in Marxist critique. What they mean is: who or what stands between your money and your intentions for it. What some economists have lately taken to calling, with a suspiciously pejorative emphasis, “decentralized cryptocurrencies”—meaning Bitcoin, Ethereum, and others—are regarded by both central and commercial banks as dangerous disintermediators; precisely because they’ve been designed to ensure equal protection for all users, with no special privileges extended to the State. This “crypto”—whose very technology was primarily created in order to correct the centralization that now threatens it—was, generally is, and should be constitutionally unconcerned with who possesses it and uses it for what. To traditional banks, however, not to mention to states with sovereign currencies, this is unacceptable: These upstart crypto-competitors represent an epochal disruption, promising the possibility of storing and moving verifiable value independent of State approval, and so placing their users beyond the reach of Rome. Opposition to such free trade is all-too-often concealed beneath a veneer of paternalistic concern, with the State claiming that in the absence of its own loving intermediation, the market will inevitably devolve into unlawful gambling dens and fleshpots rife with tax fraud, drug deals, and gun-running.  It’s difficult to countenance this claim, however, when according to none other than the Office of Terrorist Financing and Financial Crimes at the US Department of the Treasury, “Although virtual currencies are used for illicit transactions, the volume is small compared to the volume of illicit activity through traditional financial services.” Traditional financial services, of course, being the very face and definition of “intermediation”—services that seek to extract for themselves a piece of our every exchange. 4. Which brings us back to Waller—who might be called an anti-disintermediator, a defender of the commercial banking system and its services that store and invest (and often lose) the money that the American central banking system, the Fed, decides to print (often in the middle of the night). You’d be surprised how many opinion-writers are willing to publicly pretend they can’t tell the difference between an accounting trick and money-printing. And yet I admit that I still find his remarks compelling—chiefly because I reject his rationale, but concur with his conclusions. It’s Waller’s opinion, as well as my own, that the United States does not need to develop its own CBDC. Yet while Waller believes that the US doesn’t need a CBDC because of its already robust commercial banking sector, I believe that the US doesn’t need a CBDC despite the banks, whose activities are, to my mind, almost all better and more equitably accomplished these days by the robust, diverse, and sustainable ecosystem of non-State cryptocurrencies (translation: regular crypto).  I risk few readers by asserting that the commercial banking sector is not, as Waller avers, the solution, but is in fact the problem—a parasitic and utterly inefficient industry that has preyed upon its customers with an impunity backstopped by regular bail-outs from the Fed, thanks to the dubious fiction that it is “too big too fail.” But even as the banking-industrial complex has become larger, its utility has withered—especially in comparison to crypto. Commercial banking once uniquely secured otherwise risky transactions, ensuring escrow and reversibility. Similarly, credit and investment were unavailable, and perhaps even unimaginable, without it. Today you can enjoy any of these in three clicks. Still, banks have an older role. Since the inception of commercial banking, or at least since its capitalization by central banking, the industry’s most important function has been the moving of money, fulfilling the promise of those promissory notes of old by allowing their redemption in different cities, or in different countries, and by allowing bearers and redeemers of those notes to make payments on their and others’ behalf across similar distances. For most of history, moving money in such a manner required the storing of it, and in great quantities—necessitating the palpable security of vaults and guards. But as intrinsically valuable money gave way to our little napkins, and napkins give way to their intangible digital equivalents, that has changed. Today, however, there isn’t much in the vaults. If you walk into a bank, even without a mask over your face, and attempt a sizable withdrawal, you’re almost always going to be told to come back next Wednesday, as the physical currency you’re requesting has to be ordered from the rare branch or reserve that actually has it. Meanwhile, the guard, no less mythologized in the mind than the granite and marble he paces, is just an old man with tired feet, paid too little to use the gun that he carries.  These are what commercial banks have been reduced to: “intermediating” money-ordering-services that profit off penalties and fees—protected by your grandfather. In sum, in an increasingly digital society, there is almost nothing a bank can do to provide access to and protect your assets that an algorithm can’t replicate and improve upon. On the other hand, when Christmas comes around, cryptocurrencies don’t give out those little tiny desk calendars. But let’s return to close with that bank security guard, who after helping to close up the bank for the day probably goes off to work a second job, to make ends meet—at a gas station, say.  Will a CBDC be helpful to him? Will an e-dollar improve his life, more than a cash dollar would, or a dollar-equivalent in Bitcoin, or in some stablecoin, or even in an FDIC-insured stablecoin? Let’s say that his doctor has told him that the sedentary or just-standing-around nature of his work at the bank has impacted his health, and contributed to dangerous weight gain. Our guard must cut down on sugar, and his private insurance company—which he’s been publicly mandated to deal with—now starts tracking his pre-diabetic condition and passes data on that condition on to the systems that control his CBDC wallet, so that the next time he goes to the deli and tries to buy some candy, he’s rejected—he can’t—his wallet just refuses to pay, even if it was his intention to buy that candy for his granddaughter. Or, let’s say that one of his e-dollars, which he received as a tip at his gas station job, happens to be later registered by a central authority as having been used, by its previous possessor, to execute a suspicious transaction, whether it was a drug deal or a donation to a totally innocent and in fact totally life-affirming charity operating in a foreign country deemed hostile to US foreign policy, and so it becomes frozen and even has to be “civilly” forfeited. How will our beleagured guard get it back? Will he ever be able to prove that said e-dollar is legitimately his and retake possession of it, and how much would that proof ultimately cost him? Our guard earns his living with his labor—he earns it with his body, and yet by the time that body inevitably breaks down, will he have amassed enough of a grubstake to comfortably retire? And if not, can he ever hope to rely on the State’s benevolent, or even adequate, provision—for his welfare, his care, his healing?  This is the question that I’d like Waller, that I’d like all of the Fed, and the Treasury, and the rest of the US government, to answer:  Of all the things that might be centralized and nationalized in this poor man’s life, should it really be his money? Subscribe here Tyler Durden Sun, 10/10/2021 - 20:40.....»»

Category: personnelSource: nytOct 10th, 2021

Merck (MRK) to Acquire Acceleron, Build Rare Disease Portfolio

Merck (MRK) is set to acquire rare diseases-focused company Acceleron Pharma for $11.5 billion and gain access to its promising phase III candidate. Putting all rumors to rest, Merck MRK has announced that it will acquire Acceleron Pharma, Inc. XLRN for $180 per share in cash for an approximate total equity value of $11.5 billion in a bid to build its rare diseases portfolio.Acceleron, a biopharmaceutical company with a focus on rare diseases, has been in the spotlight of late on acquisition rumors that led to a surge in its share price. Bristol Myers Squibb BMY, which already owns an 11.5% stake in Acceleron, was also a likely suitor for the same.Acceleron’s stock has gained 34.5% in the year so far against the industry’s decline of 5.6%. Shares have gained steam in the last couple of weeks as the acquisition talks started doing the rounds.Image Source: Zacks Investment ResearchPer the terms, Merck, through a subsidiary, will initiate a tender offer to acquire all outstanding shares of Acceleron. The deal is expected to close in the fourth quarter of 2021.The acquisition will give Merck access to Accelereon’s promising pipeline candidate — sotatercept — which is being evaluated for the treatment of pulmonary arterial hypertension (PAH), a progressive and life-threatening blood vessel disorder. Sotatercept, currently in phase III studies as an add-on to the current standard of care for the treatment of PAH, has a novel mechanism of action with the potential to improve short-term and/or long-term clinical outcomes in PAH patients. Sotatercept is being evaluated in multiple phase III studies for the treatment of certain patients with PAH as well as a phase II study in patients with combined post- and pre-capillary pulmonary hypertension in heart failure with preserved ejection fraction. It enjoys orphan drug status and was also granted Breakthrough Therapy designation in the United StatesThis apart, Acceleron earns royalties on sales of Reblozyl (luspatercept-aamt), which has been developed as part of its global collaboration with Bristol Myers.  Reblozyl is approved for the treatment of anemia in certain rare blood disorders in the United States and Europe, among other countries.Once the acquisition is completed, Merck will receive royalty payments in the low-to-mid-20% range of global net sales of Reblozyl from Bristol Myers. For sotatercept, Merck will retain exclusive development and commercialization rights in PAH and will pay Bristol Myers a flat royalty in the low-20% range.Our TakePAH market represents a significant opportunity and the potential approval of sotatercept strengthens Merck’s cardiovascular portfolio.Assuming an approval and targeted launch in the 2024-2025 timeframe, the acquisition will diversify Merck’s revenue base. The company is highly dependent on its blockbuster immuno-oncology drug Keytruda, which in turn is slated to lose its exclusivity period later in the decade. In the conference call, management stated that the PAH market is expected to reach roughly $7.5 billion by 2026, according to EvaluatePharma.Merck’s shares have declined 8.2% so far this year against the industry’s 7.9% increase.Image Source: Zacks Investment ResearchThe acquisition should boost Merck’s top line once sotatercept gains approval. Management stated that commercial exclusivity for PAH in the United States is expected to extend through 2036-2037.However, it might not be enough to offset the decline in revenues once Keytruda loses exclusivity. While mergers & acquisitions have always taken centerstage in the pharma/biotech sector, there hasn’t been much happening on that front in the year so far, barring a few. Earlier, AstraZeneca AZN acquired Alexion for $39 billion. Nevertheless, as the economic situation improves, the pace is expected to pick up as pharma/biotech bigwigs constantly eye lucrative acquisitions to bolster their portfolio/pipeline and combat rivalry.Merck currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.      Zacks Names "Single Best Pick to Double" From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all. You know this company from its past glory days, but few would expect that it's poised for a monster turnaround. Fresh from a successful repositioning and flush with A-list celeb endorsements, it could rival or surpass other recent Zacks' Stocks Set to Double like Boston Beer Company which shot up +143.0% in a little more than 9 months and Nvidia which boomed +175.9% in one year.Free: See Our Top Stock and 4 Runners Up >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report AstraZeneca PLC (AZN): Free Stock Analysis Report Bristol Myers Squibb Company (BMY): Free Stock Analysis Report Merck & Co., Inc. (MRK): Free Stock Analysis Report Acceleron Pharma Inc. (XLRN): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research.....»»

Category: topSource: zacksOct 1st, 2021

"Damn You To Hell, You Will Not Destroy America" - Here Is The "Spartacus COVID Letter" That"s Gone Viral

"Damn You To Hell, You Will Not Destroy America" - Here Is The 'Spartacus COVID Letter' That's Gone Viral Via The Automatic Earth blog, This is an anonymously posted document by someone who calls themselves Spartacus. Because it’s anonymous, I can’t contact them to ask for permission to publish. So I hesitated for a while, but it’s simply the best document I’ve seen on Covid, vaccines, etc. Whoever Spartacus is, they have a very elaborate knowledge in “the field”. If you want to know a lot more about the no. 1 issue in the world today, read it. And don’t worry if you don’t understand every single word, neither do I. But I learned a lot. The original PDF doc is here: Covid19 – The Spartacus Letter Hello, My name is Spartacus, and I’ve had enough. We have been forced to watch America and the Free World spin into inexorable decline due to a biowarfare attack. We, along with countless others, have been victimized and gaslit by propaganda and psychological warfare operations being conducted by an unelected, unaccountable Elite against the American people and our allies. Our mental and physical health have suffered immensely over the course of the past year and a half. We have felt the sting of isolation, lockdown, masking, quarantines, and other completely nonsensical acts of healthcare theater that have done absolutely nothing to protect the health or wellbeing of the public from the ongoing COVID-19 pandemic. Now, we are watching the medical establishment inject literal poison into millions of our fellow Americans without so much as a fight. We have been told that we will be fired and denied our livelihoods if we refuse to vaccinate. This was the last straw. We have spent thousands of hours analyzing leaked footage from Wuhan, scientific papers from primary sources, as well as the paper trails left by the medical establishment. What we have discovered would shock anyone to their core. First, we will summarize our findings, and then, we will explain them in detail. References will be placed at the end. Summary: COVID-19 is a blood and blood vessel disease. SARS-CoV-2 infects the lining of human blood vessels, causing them to leak into the lungs. Current treatment protocols (e.g. invasive ventilation) are actively harmful to patients, accelerating oxidative stress and causing severe VILI (ventilator-induced lung injuries). The continued use of ventilators in the absence of any proven medical benefit constitutes mass murder. Existing countermeasures are inadequate to slow the spread of what is an aerosolized and potentially wastewater-borne virus, and constitute a form of medical theater. Various non-vaccine interventions have been suppressed by both the media and the medical establishment in favor of vaccines and expensive patented drugs. The authorities have denied the usefulness of natural immunity against COVID-19, despite the fact that natural immunity confers protection against all of the virus’s proteins, and not just one. Vaccines will do more harm than good. The antigen that these vaccines are based on, SARS-CoV- 2 Spike, is a toxic protein. SARS-CoV-2 may have ADE, or antibody-dependent enhancement; current antibodies may not neutralize future strains, but instead help them infect immune cells. Also, vaccinating during a pandemic with a leaky vaccine removes the evolutionary pressure for a virus to become less lethal. There is a vast and appalling criminal conspiracy that directly links both Anthony Fauci and Moderna to the Wuhan Institute of Virology. COVID-19 vaccine researchers are directly linked to scientists involved in brain-computer interface (“neural lace”) tech, one of whom was indicted for taking grant money from China. Independent researchers have discovered mysterious nanoparticles inside the vaccines that are not supposed to be present. The entire pandemic is being used as an excuse for a vast political and economic transformation of Western society that will enrich the already rich and turn the rest of us into serfs and untouchables. COVID-19 Pathophysiology and Treatments: COVID-19 is not a viral pneumonia. It is a viral vascular endotheliitis and attacks the lining of blood vessels, particularly the small pulmonary alveolar capillaries, leading to endothelial cell activation and sloughing, coagulopathy, sepsis, pulmonary edema, and ARDS-like symptoms. This is a disease of the blood and blood vessels. The circulatory system. Any pneumonia that it causes is secondary to that. In severe cases, this leads to sepsis, blood clots, and multiple organ failure, including hypoxic and inflammatory damage to various vital organs, such as the brain, heart, liver, pancreas, kidneys, and intestines. Some of the most common laboratory findings in COVID-19 are elevated D-dimer, elevated prothrombin time, elevated C-reactive protein, neutrophilia, lymphopenia, hypocalcemia, and hyperferritinemia, essentially matching a profile of coagulopathy and immune system hyperactivation/immune cell exhaustion. COVID-19 can present as almost anything, due to the wide tropism of SARS-CoV-2 for various tissues in the body’s vital organs. While its most common initial presentation is respiratory illness and flu-like symptoms, it can present as brain inflammation, gastrointestinal disease, or even heart attack or pulmonary embolism. COVID-19 is more severe in those with specific comorbidities, such as obesity, diabetes, and hypertension. This is because these conditions involve endothelial dysfunction, which renders the circulatory system more susceptible to infection and injury by this particular virus. The vast majority of COVID-19 cases are mild and do not cause significant disease. In known cases, there is something known as the 80/20 rule, where 80% of cases are mild and 20% are severe or critical. However, this ratio is only correct for known cases, not all infections. The number of actual infections is much, much higher. Consequently, the mortality and morbidity rate is lower. However, COVID-19 spreads very quickly, meaning that there are a significant number of severely-ill and critically-ill patients appearing in a short time frame. In those who have critical COVID-19-induced sepsis, hypoxia, coagulopathy, and ARDS, the most common treatments are intubation, injected corticosteroids, and blood thinners. This is not the correct treatment for COVID-19. In severe hypoxia, cellular metabolic shifts cause ATP to break down into hypoxanthine, which, upon the reintroduction of oxygen, causes xanthine oxidase to produce tons of highly damaging radicals that attack tissue. This is called ischemia-reperfusion injury, and it’s why the majority of people who go on a ventilator are dying. In the mitochondria, succinate buildup due to sepsis does the same exact thing; when oxygen is reintroduced, it makes superoxide radicals. Make no mistake, intubation will kill people who have COVID-19. The end-stage of COVID-19 is severe lipid peroxidation, where fats in the body start to “rust” due to damage by oxidative stress. This drives autoimmunity. Oxidized lipids appear as foreign objects to the immune system, which recognizes and forms antibodies against OSEs, or oxidation-specific epitopes. Also, oxidized lipids feed directly into pattern recognition receptors, triggering even more inflammation and summoning even more cells of the innate immune system that release even more destructive enzymes. This is similar to the pathophysiology of Lupus. COVID-19’s pathology is dominated by extreme oxidative stress and neutrophil respiratory burst, to the point where hemoglobin becomes incapable of carrying oxygen due to heme iron being stripped out of heme by hypochlorous acid. No amount of supplemental oxygen can oxygenate blood that chemically refuses to bind O2. The breakdown of the pathology is as follows: SARS-CoV-2 Spike binds to ACE2. Angiotensin Converting Enzyme 2 is an enzyme that is part of the renin-angiotensin-aldosterone system, or RAAS. The RAAS is a hormone control system that moderates fluid volume in the body and in the bloodstream (i.e. osmolarity) by controlling salt retention and excretion. This protein, ACE2, is ubiquitous in every part of the body that interfaces with the circulatory system, particularly in vascular endothelial cells and pericytes, brain astrocytes, renal tubules and podocytes, pancreatic islet cells, bile duct and intestinal epithelial cells, and the seminiferous ducts of the testis, all of which SARS-CoV-2 can infect, not just the lungs. SARS-CoV-2 infects a cell as follows: SARS-CoV-2 Spike undergoes a conformational change where the S1 trimers flip up and extend, locking onto ACE2 bound to the surface of a cell. TMPRSS2, or transmembrane protease serine 2, comes along and cuts off the heads of the Spike, exposing the S2 stalk-shaped subunit inside. The remainder of the Spike undergoes a conformational change that causes it to unfold like an extension ladder, embedding itself in the cell membrane. Then, it folds back upon itself, pulling the viral membrane and the cell membrane together. The two membranes fuse, with the virus’s proteins migrating out onto the surface of the cell. The SARS-CoV-2 nucleocapsid enters the cell, disgorging its genetic material and beginning the viral replication process, hijacking the cell’s own structures to produce more virus. SARS-CoV-2 Spike proteins embedded in a cell can actually cause human cells to fuse together, forming syncytia/MGCs (multinuclear giant cells). They also have other pathogenic, harmful effects. SARS-CoV- 2’s viroporins, such as its Envelope protein, act as calcium ion channels, introducing calcium into infected cells. The virus suppresses the natural interferon response, resulting in delayed inflammation. SARS-CoV-2 N protein can also directly activate the NLRP3 inflammasome. Also, it suppresses the Nrf2 antioxidant pathway. The suppression of ACE2 by binding with Spike causes a buildup of bradykinin that would otherwise be broken down by ACE2. This constant calcium influx into the cells results in (or is accompanied by) noticeable hypocalcemia, or low blood calcium, especially in people with Vitamin D deficiencies and pre-existing endothelial dysfunction. Bradykinin upregulates cAMP, cGMP, COX, and Phospholipase C activity. This results in prostaglandin release and vastly increased intracellular calcium signaling, which promotes highly aggressive ROS release and ATP depletion. NADPH oxidase releases superoxide into the extracellular space. Superoxide radicals react with nitric oxide to form peroxynitrite. Peroxynitrite reacts with the tetrahydrobiopterin cofactor needed by endothelial nitric oxide synthase, destroying it and “uncoupling” the enzymes, causing nitric oxide synthase to synthesize more superoxide instead. This proceeds in a positive feedback loop until nitric oxide bioavailability in the circulatory system is depleted. Dissolved nitric oxide gas produced constantly by eNOS serves many important functions, but it is also antiviral against SARS-like coronaviruses, preventing the palmitoylation of the viral Spike protein and making it harder for it to bind to host receptors. The loss of NO allows the virus to begin replicating with impunity in the body. Those with endothelial dysfunction (i.e. hypertension, diabetes, obesity, old age, African-American race) have redox equilibrium issues to begin with, giving the virus an advantage. Due to the extreme cytokine release triggered by these processes, the body summons a great deal of neutrophils and monocyte-derived alveolar macrophages to the lungs. Cells of the innate immune system are the first-line defenders against pathogens. They work by engulfing invaders and trying to attack them with enzymes that produce powerful oxidants, like SOD and MPO. Superoxide dismutase takes superoxide and makes hydrogen peroxide, and myeloperoxidase takes hydrogen peroxide and chlorine ions and makes hypochlorous acid, which is many, many times more reactive than sodium hypochlorite bleach. Neutrophils have a nasty trick. They can also eject these enzymes into the extracellular space, where they will continuously spit out peroxide and bleach into the bloodstream. This is called neutrophil extracellular trap formation, or, when it becomes pathogenic and counterproductive, NETosis. In severe and critical COVID-19, there is actually rather severe NETosis. Hypochlorous acid building up in the bloodstream begins to bleach the iron out of heme and compete for O2 binding sites. Red blood cells lose the ability to transport oxygen, causing the sufferer to turn blue in the face. Unliganded iron, hydrogen peroxide, and superoxide in the bloodstream undergo the Haber- Weiss and Fenton reactions, producing extremely reactive hydroxyl radicals that violently strip electrons from surrounding fats and DNA, oxidizing them severely. This condition is not unknown to medical science. The actual name for all of this is acute sepsis. We know this is happening in COVID-19 because people who have died of the disease have noticeable ferroptosis signatures in their tissues, as well as various other oxidative stress markers such as nitrotyrosine, 4-HNE, and malondialdehyde. When you intubate someone with this condition, you are setting off a free radical bomb by supplying the cells with O2. It’s a catch-22, because we need oxygen to make Adenosine Triphosphate (that is, to live), but O2 is also the precursor of all these damaging radicals that lead to lipid peroxidation. The correct treatment for severe COVID-19 related sepsis is non-invasive ventilation, steroids, and antioxidant infusions. Most of the drugs repurposed for COVID-19 that show any benefit whatsoever in rescuing critically-ill COVID-19 patients are antioxidants. N-acetylcysteine, melatonin, fluvoxamine, budesonide, famotidine, cimetidine, and ranitidine are all antioxidants. Indomethacin prevents iron- driven oxidation of arachidonic acid to isoprostanes. There are powerful antioxidants such as apocynin that have not even been tested on COVID-19 patients yet which could defang neutrophils, prevent lipid peroxidation, restore endothelial health, and restore oxygenation to the tissues. Scientists who know anything about pulmonary neutrophilia, ARDS, and redox biology have known or surmised much of this since March 2020. In April 2020, Swiss scientists confirmed that COVID-19 was a vascular endotheliitis. By late 2020, experts had already concluded that COVID-19 causes a form of viral sepsis. They also know that sepsis can be effectively treated with antioxidants. None of this information is particularly new, and yet, for the most part, it has not been acted upon. Doctors continue to use damaging intubation techniques with high PEEP settings despite high lung compliance and poor oxygenation, killing an untold number of critically ill patients with medical malpractice. Because of the way they are constructed, Randomized Control Trials will never show any benefit for any antiviral against COVID-19. Not Remdesivir, not Kaletra, not HCQ, and not Ivermectin. The reason for this is simple; for the patients that they have recruited for these studies, such as Oxford’s ludicrous RECOVERY study, the intervention is too late to have any positive effect. The clinical course of COVID-19 is such that by the time most people seek medical attention for hypoxia, their viral load has already tapered off to almost nothing. If someone is about 10 days post-exposure and has already been symptomatic for five days, there is hardly any virus left in their bodies, only cellular damage and derangement that has initiated a hyperinflammatory response. It is from this group that the clinical trials for antivirals have recruited, pretty much exclusively. In these trials, they give antivirals to severely ill patients who have no virus in their bodies, only a delayed hyperinflammatory response, and then absurdly claim that antivirals have no utility in treating or preventing COVID-19. These clinical trials do not recruit people who are pre-symptomatic. They do not test pre-exposure or post-exposure prophylaxis. This is like using a defibrillator to shock only flatline, and then absurdly claiming that defibrillators have no medical utility whatsoever when the patients refuse to rise from the dead. The intervention is too late. These trials for antivirals show systematic, egregious selection bias. They are providing a treatment that is futile to the specific cohort they are enrolling. India went against the instructions of the WHO and mandated the prophylactic usage of Ivermectin. They have almost completely eradicated COVID-19. The Indian Bar Association of Mumbai has brought criminal charges against WHO Chief Scientist Dr. Soumya Swaminathan for recommending against the use of Ivermectin. Ivermectin is not “horse dewormer”. Yes, it is sold in veterinary paste form as a dewormer for animals. It has also been available in pill form for humans for decades, as an antiparasitic drug. The media have disingenuously claimed that because Ivermectin is an antiparasitic drug, it has no utility as an antivirus. This is incorrect. Ivermectin has utility as an antiviral. It blocks importin, preventing nuclear import, effectively inhibiting viral access to cell nuclei. Many drugs currently on the market have multiple modes of action. Ivermectin is one such drug. It is both antiparasitic and antiviral. In Bangladesh, Ivermectin costs $1.80 for an entire 5-day course. Remdesivir, which is toxic to the liver, costs $3,120 for a 5-day course of the drug. Billions of dollars of utterly useless Remdesivir were sold to our governments on the taxpayer’s dime, and it ended up being totally useless for treating hyperinflammatory COVID-19. The media has hardly even covered this at all. The opposition to the use of generic Ivermectin is not based in science. It is purely financially and politically-motivated. An effective non-vaccine intervention would jeopardize the rushed FDA approval of patented vaccines and medicines for which the pharmaceutical industry stands to rake in billions upon billions of dollars in sales on an ongoing basis. The majority of the public are scientifically illiterate and cannot grasp what any of this even means, thanks to a pathetic educational system that has miseducated them. You would be lucky to find 1 in 100 people who have even the faintest clue what any of this actually means. COVID-19 Transmission: COVID-19 is airborne. The WHO carried water for China by claiming that the virus was only droplet- borne. Our own CDC absurdly claimed that it was mostly transmitted by fomite-to-face contact, which, given its rapid spread from Wuhan to the rest of the world, would have been physically impossible. The ridiculous belief in fomite-to-face being a primary mode of transmission led to the use of surface disinfection protocols that wasted time, energy, productivity, and disinfectant. The 6-foot guidelines are absolutely useless. The minimum safe distance to protect oneself from an aerosolized virus is to be 15+ feet away from an infected person, no closer. Realistically, no public transit is safe. Surgical masks do not protect you from aerosols. The virus is too small and the filter media has too large of gaps to filter it out. They may catch respiratory droplets and keep the virus from being expelled by someone who is sick, but they do not filter a cloud of infectious aerosols if someone were to walk into said cloud. The minimum level of protection against this virus is quite literally a P100 respirator, a PAPR/CAPR, or a 40mm NATO CBRN respirator, ideally paired with a full-body tyvek or tychem suit, gloves, and booties, with all the holes and gaps taped. Live SARS-CoV-2 may potentially be detected in sewage outflows, and there may be oral-fecal transmission. During the SARS outbreak in 2003, in the Amoy Gardens incident, hundreds of people were infected by aerosolized fecal matter rising from floor drains in their apartments. COVID-19 Vaccine Dangers: The vaccines for COVID-19 are not sterilizing and do not prevent infection or transmission. They are “leaky” vaccines. This means they remove the evolutionary pressure on the virus to become less lethal. It also means that the vaccinated are perfect carriers. In other words, those who are vaccinated are a threat to the unvaccinated, not the other way around. All of the COVID-19 vaccines currently in use have undergone minimal testing, with highly accelerated clinical trials. Though they appear to limit severe illness, the long-term safety profile of these vaccines remains unknown. Some of these so-called “vaccines” utilize an untested new technology that has never been used in vaccines before. Traditional vaccines use weakened or killed virus to stimulate an immune response. The Moderna and Pfizer-BioNTech vaccines do not. They are purported to consist of an intramuscular shot containing a suspension of lipid nanoparticles filled with messenger RNA. The way they generate an immune response is by fusing with cells in a vaccine recipient’s shoulder, undergoing endocytosis, releasing their mRNA cargo into those cells, and then utilizing the ribosomes in those cells to synthesize modified SARS-CoV-2 Spike proteins in-situ. These modified Spike proteins then migrate to the surface of the cell, where they are anchored in place by a transmembrane domain. The adaptive immune system detects the non-human viral protein being expressed by these cells, and then forms antibodies against that protein. This is purported to confer protection against the virus, by training the adaptive immune system to recognize and produce antibodies against the Spike on the actual virus. The J&J and AstraZeneca vaccines do something similar, but use an adenovirus vector for genetic material delivery instead of a lipid nanoparticle. These vaccines were produced or validated with the aid of fetal cell lines HEK-293 and PER.C6, which people with certain religious convictions may object strongly to. SARS-CoV-2 Spike is a highly pathogenic protein on its own. It is impossible to overstate the danger presented by introducing this protein into the human body. It is claimed by vaccine manufacturers that the vaccine remains in cells in the shoulder, and that SARS- CoV-2 Spike produced and expressed by these cells from the vaccine’s genetic material is harmless and inert, thanks to the insertion of prolines in the Spike sequence to stabilize it in the prefusion conformation, preventing the Spike from becoming active and fusing with other cells. However, a pharmacokinetic study from Japan showed that the lipid nanoparticles and mRNA from the Pfizer vaccine did not stay in the shoulder, and in fact bioaccumulated in many different organs, including the reproductive organs and adrenal glands, meaning that modified Spike is being expressed quite literally all over the place. These lipid nanoparticles may trigger anaphylaxis in an unlucky few, but far more concerning is the unregulated expression of Spike in various somatic cell lines far from the injection site and the unknown consequences of that. Messenger RNA is normally consumed right after it is produced in the body, being translated into a protein by a ribosome. COVID-19 vaccine mRNA is produced outside the body, long before a ribosome translates it. In the meantime, it could accumulate damage if inadequately preserved. When a ribosome attempts to translate a damaged strand of mRNA, it can become stalled. When this happens, the ribosome becomes useless for translating proteins because it now has a piece of mRNA stuck in it, like a lace card in an old punch card reader. The whole thing has to be cleaned up and new ribosomes synthesized to replace it. In cells with low ribosome turnover, like nerve cells, this can lead to reduced protein synthesis, cytopathic effects, and neuropathies. Certain proteins, including SARS-CoV-2 Spike, have proteolytic cleavage sites that are basically like little dotted lines that say “cut here”, which attract a living organism’s own proteases (essentially, molecular scissors) to cut them. There is a possibility that S1 may be proteolytically cleaved from S2, causing active S1 to float away into the bloodstream while leaving the S2 “stalk” embedded in the membrane of the cell that expressed the protein. SARS-CoV-2 Spike has a Superantigenic region (SAg), which may promote extreme inflammation. Anti-Spike antibodies were found in one study to function as autoantibodies and attack the body’s own cells. Those who have been immunized with COVID-19 vaccines have developed blood clots, myocarditis, Guillain-Barre Syndrome, Bell’s Palsy, and multiple sclerosis flares, indicating that the vaccine promotes autoimmune reactions against healthy tissue. SARS-CoV-2 Spike does not only bind to ACE2. It was suspected to have regions that bind to basigin, integrins, neuropilin-1, and bacterial lipopolysaccharides as well. SARS-CoV-2 Spike, on its own, can potentially bind any of these things and act as a ligand for them, triggering unspecified and likely highly inflammatory cellular activity. SARS-CoV-2 Spike contains an unusual PRRA insert that forms a furin cleavage site. Furin is a ubiquitous human protease, making this an ideal property for the Spike to have, giving it a high degree of cell tropism. No wild-type SARS-like coronaviruses related to SARS-CoV-2 possess this feature, making it highly suspicious, and perhaps a sign of human tampering. SARS-CoV-2 Spike has a prion-like domain that enhances its infectiousness. The Spike S1 RBD may bind to heparin-binding proteins and promote amyloid aggregation. In humans, this could lead to Parkinson’s, Lewy Body Dementia, premature Alzheimer’s, or various other neurodegenerative diseases. This is very concerning because SARS-CoV-2 S1 is capable of injuring and penetrating the blood-brain barrier and entering the brain. It is also capable of increasing the permeability of the blood-brain barrier to other molecules. SARS-CoV-2, like other betacoronaviruses, may have Dengue-like ADE, or antibody-dependent enhancement of disease. For those who aren’t aware, some viruses, including betacoronaviruses, have a feature called ADE. There is also something called Original Antigenic Sin, which is the observation that the body prefers to produce antibodies based on previously-encountered strains of a virus over newly- encountered ones. In ADE, antibodies from a previous infection become non-neutralizing due to mutations in the virus’s proteins. These non-neutralizing antibodies then act as trojan horses, allowing live, active virus to be pulled into macrophages through their Fc receptor pathways, allowing the virus to infect immune cells that it would not have been able to infect before. This has been known to happen with Dengue Fever; when someone gets sick with Dengue, recovers, and then contracts a different strain, they can get very, very ill. If someone is vaccinated with mRNA based on the Spike from the initial Wuhan strain of SARS-CoV-2, and then they become infected with a future, mutated strain of the virus, they may become severely ill. In other words, it is possible for vaccines to sensitize someone to disease. There is a precedent for this in recent history. Sanofi’s Dengvaxia vaccine for Dengue failed because it caused immune sensitization in people whose immune systems were Dengue-naive. In mice immunized against SARS-CoV and challenged with the virus, a close relative of SARS-CoV-2, they developed immune sensitization, Th2 immunopathology, and eosinophil infiltration in their lungs. We have been told that SARS-CoV-2 mRNA vaccines cannot be integrated into the human genome, because messenger RNA cannot be turned back into DNA. This is false. There are elements in human cells called LINE-1 retrotransposons, which can indeed integrate mRNA into a human genome by endogenous reverse transcription. Because the mRNA used in the vaccines is stabilized, it hangs around in cells longer, increasing the chances for this to happen. If the gene for SARS-CoV-2 Spike is integrated into a portion of the genome that is not silent and actually expresses a protein, it is possible that people who take this vaccine may continuously express SARS-CoV-2 Spike from their somatic cells for the rest of their lives. By inoculating people with a vaccine that causes their bodies to produce Spike in-situ, they are being inoculated with a pathogenic protein. A toxin that may cause long-term inflammation, heart problems, and a raised risk of cancers. In the long-term, it may also potentially lead to premature neurodegenerative disease. Absolutely nobody should be compelled to take this vaccine under any circumstances, and in actual fact, the vaccination campaign must be stopped immediately. COVID-19 Criminal Conspiracy: The vaccine and the virus were made by the same people. In 2014, there was a moratorium on SARS gain-of-function research that lasted until 2017. This research was not halted. Instead, it was outsourced, with the federal grants being laundered through NGOs. Ralph Baric is a virologist and SARS expert at UNC Chapel Hill in North Carolina. This is who Anthony Fauci was referring to when he insisted, before Congress, that if any gain-of-function research was being conducted, it was being conducted in North Carolina. This was a lie. Anthony Fauci lied before Congress. A felony. Ralph Baric and Shi Zhengli are colleagues and have co-written papers together. Ralph Baric mentored Shi Zhengli in his gain-of-function manipulation techniques, particularly serial passage, which results in a virus that appears as if it originated naturally. In other words, deniable bioweapons. Serial passage in humanized hACE2 mice may have produced something like SARS-CoV-2. The funding for the gain-of-function research being conducted at the Wuhan Institute of Virology came from Peter Daszak. Peter Daszak runs an NGO called EcoHealth Alliance. EcoHealth Alliance received millions of dollars in grant money from the National Institutes of Health/National Institute of Allergy and Infectious Diseases (that is, Anthony Fauci), the Defense Threat Reduction Agency (part of the US Department of Defense), and the United States Agency for International Development. NIH/NIAID contributed a few million dollars, and DTRA and USAID each contributed tens of millions of dollars towards this research. Altogether, it was over a hundred million dollars. EcoHealth Alliance subcontracted these grants to the Wuhan Institute of Virology, a lab in China with a very questionable safety record and poorly trained staff, so that they could conduct gain-of-function research, not in their fancy P4 lab, but in a level-2 lab where technicians wore nothing more sophisticated than perhaps a hairnet, latex gloves, and a surgical mask, instead of the bubble suits used when working with dangerous viruses. Chinese scientists in Wuhan reported being routinely bitten and urinated on by laboratory animals. Why anyone would outsource this dangerous and delicate work to the People’s Republic of China, a country infamous for industrial accidents and massive explosions that have claimed hundreds of lives, is completely beyond me, unless the aim was to start a pandemic on purpose. In November of 2019, three technicians at the Wuhan Institute of Virology developed symptoms consistent with a flu-like illness. Anthony Fauci, Peter Daszak, and Ralph Baric knew at once what had happened, because back channels exist between this laboratory and our scientists and officials. December 12th, 2019, Ralph Baric signed a Material Transfer Agreement (essentially, an NDA) to receive Coronavirus mRNA vaccine-related materials co-owned by Moderna and NIH. It wasn’t until a whole month later, on January 11th, 2020, that China allegedly sent us the sequence to what would become known as SARS-CoV-2. Moderna claims, rather absurdly, that they developed a working vaccine from this sequence in under 48 hours. Stephane Bancel, the current CEO of Moderna, was formerly the CEO of bioMerieux, a French multinational corporation specializing in medical diagnostic tech, founded by one Alain Merieux. Alain Merieux was one of the individuals who was instrumental in the construction of the Wuhan Institute of Virology’s P4 lab. The sequence given as the closest relative to SARS-CoV-2, RaTG13, is not a real virus. It is a forgery. It was made by entering a gene sequence by hand into a database, to create a cover story for the existence of SARS-CoV-2, which is very likely a gain-of-function chimera produced at the Wuhan Institute of Virology and was either leaked by accident or intentionally released. The animal reservoir of SARS-CoV-2 has never been found. This is not a conspiracy “theory”. It is an actual criminal conspiracy, in which people connected to the development of Moderna’s mRNA-1273 are directly connected to the Wuhan Institute of Virology and their gain-of-function research by very few degrees of separation, if any. The paper trail is well- established. The lab-leak theory has been suppressed because pulling that thread leads one to inevitably conclude that there is enough circumstantial evidence to link Moderna, the NIH, the WIV, and both the vaccine and the virus’s creation together. In a sane country, this would have immediately led to the world’s biggest RICO and mass murder case. Anthony Fauci, Peter Daszak, Ralph Baric, Shi Zhengli, and Stephane Bancel, and their accomplices, would have been indicted and prosecuted to the fullest extent of the law. Instead, billions of our tax dollars were awarded to the perpetrators. The FBI raided Allure Medical in Shelby Township north of Detroit for billing insurance for “fraudulent COVID-19 cures”. The treatment they were using? Intravenous Vitamin C. An antioxidant. Which, as described above, is an entirely valid treatment for COVID-19-induced sepsis, and indeed, is now part of the MATH+ protocol advanced by Dr. Paul E. Marik. The FDA banned ranitidine (Zantac) due to supposed NDMA (N-nitrosodimethylamine) contamination. Ranitidine is not only an H2 blocker used as antacid, but also has a powerful antioxidant effect, scavenging hydroxyl radicals. This gives it utility in treating COVID-19. The FDA also attempted to take N-acetylcysteine, a harmless amino acid supplement and antioxidant, off the shelves, compelling Amazon to remove it from their online storefront. This leaves us with a chilling question: did the FDA knowingly suppress antioxidants useful for treating COVID-19 sepsis as part of a criminal conspiracy against the American public? The establishment is cooperating with, and facilitating, the worst criminals in human history, and are actively suppressing non-vaccine treatments and therapies in order to compel us to inject these criminals’ products into our bodies. This is absolutely unacceptable. COVID-19 Vaccine Development and Links to Transhumanism: This section deals with some more speculative aspects of the pandemic and the medical and scientific establishment’s reaction to it, as well as the disturbing links between scientists involved in vaccine research and scientists whose work involved merging nanotechnology with living cells. On June 9th, 2020, Charles Lieber, a Harvard nanotechnology researcher with decades of experience, was indicted by the DOJ for fraud. Charles Lieber received millions of dollars in grant money from the US Department of Defense, specifically the military think tanks DARPA, AFOSR, and ONR, as well as NIH and MITRE. His specialty is the use of silicon nanowires in lieu of patch clamp electrodes to monitor and modulate intracellular activity, something he has been working on at Harvard for the past twenty years. He was claimed to have been working on silicon nanowire batteries in China, but none of his colleagues can recall him ever having worked on battery technology in his life; all of his research deals with bionanotechnology, or the blending of nanotech with living cells. The indictment was over his collaboration with the Wuhan University of Technology. He had double- dipped, against the terms of his DOD grants, and taken money from the PRC’s Thousand Talents plan, a program which the Chinese government uses to bribe Western scientists into sharing proprietary R&D information that can be exploited by the PLA for strategic advantage. Charles Lieber’s own papers describe the use of silicon nanowires for brain-computer interfaces, or “neural lace” technology. His papers describe how neurons can endocytose whole silicon nanowires or parts of them, monitoring and even modulating neuronal activity. Charles Lieber was a colleague of Robert Langer. Together, along with Daniel S. Kohane, they worked on a paper describing artificial tissue scaffolds that could be implanted in a human heart to monitor its activity remotely. Robert Langer, an MIT alumnus and expert in nanotech drug delivery, is one of the co-founders of Moderna. His net worth is now $5.1 billion USD thanks to Moderna’s mRNA-1273 vaccine sales. Both Charles Lieber and Robert Langer’s bibliographies describe, essentially, techniques for human enhancement, i.e. transhumanism. Klaus Schwab, the founder of the World Economic Forum and the architect behind the so-called “Great Reset”, has long spoken of the “blending of biology and machinery” in his books. Since these revelations, it has come to the attention of independent researchers that the COVID-19 vaccines may contain reduced graphene oxide nanoparticles. Japanese researchers have also found unexplained contaminants in COVID-19 vaccines. Graphene oxide is an anxiolytic. It has been shown to reduce the anxiety of laboratory mice when injected into their brains. Indeed, given SARS-CoV-2 Spike’s propensity to compromise the blood-brain barrier and increase its permeability, it is the perfect protein for preparing brain tissue for extravasation of nanoparticles from the bloodstream and into the brain. Graphene is also highly conductive and, in some circumstances, paramagnetic. In 2013, under the Obama administration, DARPA launched the BRAIN Initiative; BRAIN is an acronym for Brain Research Through Advancing Innovative Neurotechnologies®. This program involves the development of brain-computer interface technologies for the military, particularly non-invasive, injectable systems that cause minimal damage to brain tissue when removed. Supposedly, this technology would be used for healing wounded soldiers with traumatic brain injuries, the direct brain control of prosthetic limbs, and even new abilities such as controlling drones with one’s mind. Various methods have been proposed for achieving this, including optogenetics, magnetogenetics, ultrasound, implanted electrodes, and transcranial electromagnetic stimulation. In all instances, the goal is to obtain read or read-write capability over neurons, either by stimulating and probing them, or by rendering them especially sensitive to stimulation and probing. However, the notion of the widespread use of BCI technology, such as Elon Musk’s Neuralink device, raises many concerns over privacy and personal autonomy. Reading from neurons is problematic enough on its own. Wireless brain-computer interfaces may interact with current or future wireless GSM infrastructure, creating neurological data security concerns. A hacker or other malicious actor may compromise such networks to obtain people’s brain data, and then exploit it for nefarious purposes. However, a device capable of writing to human neurons, not just reading from them, presents another, even more serious set of ethical concerns. A BCI that is capable of altering the contents of one’s mind for innocuous purposes, such as projecting a heads-up display onto their brain’s visual center or sending audio into one’s auditory cortex, would also theoretically be capable of altering mood and personality, or perhaps even subjugating someone’s very will, rendering them utterly obedient to authority. This technology would be a tyrant’s wet dream. Imagine soldiers who would shoot their own countrymen without hesitation, or helpless serfs who are satisfied to live in literal dog kennels. BCIs could be used to unscrupulously alter perceptions of basic things such as emotions and values, changing people’s thresholds of satiety, happiness, anger, disgust, and so forth. This is not inconsequential. Someone’s entire regime of behaviors could be altered by a BCI, including such things as suppressing their appetite or desire for virtually anything on Maslow’s Hierarchy of Needs. Anything is possible when you have direct access to someone’s brain and its contents. Someone who is obese could be made to feel disgust at the sight of food. Someone who is involuntarily celibate could have their libido disabled so they don’t even desire sex to begin with. Someone who is racist could be forced to feel delight over cohabiting with people of other races. Someone who is violent could be forced to be meek and submissive. These things might sound good to you if you are a tyrant, but to normal people, the idea of personal autonomy being overridden to such a degree is appalling. For the wealthy, neural laces would be an unequaled boon, giving them the opportunity to enhance their intelligence with neuroprosthetics (i.e. an “exocortex”), and to deliver irresistible commands directly into the minds of their BCI-augmented servants, even physically or sexually abusive commands that they would normally refuse. If the vaccine is a method to surreptitiously introduce an injectable BCI into millions of people without their knowledge or consent, then what we are witnessing is the rise of a tyrannical regime unlike anything ever seen before on the face of this planet, one that fully intends to strip every man, woman, and child of our free will. Our flaws are what make us human. A utopia arrived at by removing people’s free will is not a utopia at all. It is a monomaniacal nightmare. Furthermore, the people who rule over us are Dark Triad types who cannot be trusted with such power. Imagine being beaten and sexually assaulted by a wealthy and powerful psychopath and being forced to smile and laugh over it because your neural lace gives you no choice but to obey your master. The Elites are forging ahead with this technology without giving people any room to question the social or ethical ramifications, or to establish regulatory frameworks that ensure that our personal agency and autonomy will not be overridden by these devices. They do this because they secretly dream of a future where they can treat you worse than an animal and you cannot even fight back. If this evil plan is allowed to continue, it will spell the end of humanity as we know it. Conclusions: The current pandemic was produced and perpetuated by the establishment, through the use of a virus engineered in a PLA-connected Chinese biowarfare laboratory, with the aid of American taxpayer dollars and French expertise. This research was conducted under the absolutely ridiculous euphemism of “gain-of-function” research, which is supposedly carried out in order to determine which viruses have the highest potential for zoonotic spillover and preemptively vaccinate or guard against them. Gain-of-function/gain-of-threat research, a.k.a. “Dual-Use Research of Concern”, or DURC, is bioweapon research by another, friendlier-sounding name, simply to avoid the taboo of calling it what it actually is. It has always been bioweapon research. The people who are conducting this research fully understand that they are taking wild pathogens that are not infectious in humans and making them more infectious, often taking grants from military think tanks encouraging them to do so. These virologists conducting this type of research are enemies of their fellow man, like pyromaniac firefighters. GOF research has never protected anyone from any pandemic. In fact, it has now started one, meaning its utility for preventing pandemics is actually negative. It should have been banned globally, and the lunatics performing it should have been put in straitjackets long ago. Either through a leak or an intentional release from the Wuhan Institute of Virology, a deadly SARS strain is now endemic across the globe, after the WHO and CDC and public officials first downplayed the risks, and then intentionally incited a panic and lockdowns that jeopardized people’s health and their livelihoods. This was then used by the utterly depraved and psychopathic aristocratic class who rule over us as an excuse to coerce people into accepting an injected poison which may be a depopulation agent, a mind control/pacification agent in the form of injectable “smart dust”, or both in one. They believe they can get away with this by weaponizing the social stigma of vaccine refusal. They are incorrect. Their motives are clear and obvious to anyone who has been paying attention. These megalomaniacs have raided the pension funds of the free world. Wall Street is insolvent and has had an ongoing liquidity crisis since the end of 2019. The aim now is to exert total, full-spectrum physical, mental, and financial control over humanity before we realize just how badly we’ve been extorted by these maniacs. The pandemic and its response served multiple purposes for the Elite: Concealing a depression brought on by the usurious plunder of our economies conducted by rentier-capitalists and absentee owners who produce absolutely nothing of any value to society whatsoever. Instead of us having a very predictable Occupy Wall Street Part II, the Elites and their stooges got to stand up on television and paint themselves as wise and all-powerful saviors instead of the marauding cabal of despicable land pirates that they are. Destroying small businesses and eroding the middle class. Transferring trillions of dollars of wealth from the American public and into the pockets of billionaires and special interests. Engaging in insider trading, buying stock in biotech companies and shorting brick-and-mortar businesses and travel companies, with the aim of collapsing face-to-face commerce and tourism and replacing it with e-commerce and servitization. Creating a casus belli for war with China, encouraging us to attack them, wasting American lives and treasure and driving us to the brink of nuclear armageddon. Establishing technological and biosecurity frameworks for population control and technocratic- socialist “smart cities” where everyone’s movements are despotically tracked, all in anticipation of widespread automation, joblessness, and food shortages, by using the false guise of a vaccine to compel cooperation. Any one of these things would constitute a vicious rape of Western society. Taken together, they beggar belief; they are a complete inversion of our most treasured values. What is the purpose of all of this? One can only speculate as to the perpetrators’ motives, however, we have some theories. The Elites are trying to pull up the ladder, erase upward mobility for large segments of the population, cull political opponents and other “undesirables”, and put the remainder of humanity on a tight leash, rationing our access to certain goods and services that they have deemed “high-impact”, such as automobile use, tourism, meat consumption, and so on. Naturally, they will continue to have their own luxuries, as part of a strict caste system akin to feudalism. Why are they doing this? Simple. The Elites are Neo-Malthusians and believe that we are overpopulated and that resource depletion will collapse civilization in a matter of a few short decades. They are not necessarily incorrect in this belief. We are overpopulated, and we are consuming too many resources. However, orchestrating such a gruesome and murderous power grab in response to a looming crisis demonstrates that they have nothing but the utmost contempt for their fellow man. To those who are participating in this disgusting farce without any understanding of what they are doing, we have one word for you. Stop. You are causing irreparable harm to your country and to your fellow citizens. To those who may be reading this warning and have full knowledge and understanding of what they are doing and how it will unjustly harm millions of innocent people, we have a few more words. Damn you to hell. You will not destroy America and the Free World, and you will not have your New World Order. We will make certain of that. *  *  * This PDF document contains 14 pages, followed by another 17 pages of references. For those, please visit the original PDF file at Covid19 – The Spartacus Letter. *  *  * We try to run the Automatic Earth on donations. Since ad revenue has collapsed, you are now not just a reader, but an integral part of the process that builds this site. Thank you for your support. Support the Automatic Earth in virustime. Donate with Paypal, Bitcoin and Patreon. Tyler Durden Mon, 09/27/2021 - 00:00.....»»

Category: dealsSource: nytSep 27th, 2021

The 15 best Apple Arcade games that make a subscription worthwhile

Apple Arcade offers some of the best mobile games for $4.99 per month. Here are 15 games you should check out. Apple Arcade has a vast and expanding catalog of compelling games.Future Publishing/Getty Images Apple Arcade offers some of the best mobile games for $4.99 per month for iPhone, iPad, Apple TV, and Mac. Games in Apple Arcade don't have ads or in-game purchases.  Here are 15 of the best games to check out if you are new to Apple Arcade. If you're in the market for new gameplay on your Apple devices, an Apple Arcade subscription is likely a worthwhile investment. What is Apple Arcade?Apple Arcade is a gaming subscription service that, for $4.99 a month, gives Apple users access to hundreds of curated, high-quality game titles, none of which have ads or additional purchases. You might consider Apple Arcade the antidote to typical mobile games, many of which lean into in-game ads, in-game purchases, and rudimentary gameplay. Apple Arcade isn't limited just to iPhone and iPad users, either; games can also be played on Apple TV and the Mac. In addition, the subscription can be shared between up to six people via Apple's Family Sharing feature. Here are 15 of the best games currently available with a subscription to Apple Arcade. Mini MotorwaysSort of like SimCity but focused exclusively on building roads, Mini Motorways challenges you to keep traffic moving as a city expands. You'll need to accommodate increasing color-coded traffic by laying down streets, bridges, traffic lights, and highways to turn a small town into a  metropolis. Somehow soothing and nail-biting at the same time. Build roads and manage traffic in Mini Motorways.Dave Johnson/InsiderMutazioneIf you're looking for a game that is more thoughtful than the typical arcade shooter or RPG adventure, Mutazione might be just what the doctor ordered. A charming, slow-paced 2D point-and-click adventure, it's heavy on dialog and story and light on action. You follow the adventure of a teenage girl who visits her sick grandfather, and interacts with a surreal cast of local characters to complete quests and unravel a mystery.Sneaky SasquatchSneaky Sasquatch reimagines Yogi Bear as Bigfoot, and you play the titular character as you dash around the great outdoors, hiding from humans while simultaneously stealing their food and performing simple quests. You can walk, run, hide in tents, break into homes to use the kitchen, drive golf carts to get around faster, and more. It's a fun and relaxing open-ended game that's like playing a goofy wildlife-themed version of Grand Theft Auto. Play out wacky Yogi Bear adventures as Bigfoot in Sneaky Sasquatch.Dave Johnson/InsiderWhat The Golf?Technically a golf title in perhaps the strictest sense, you don't have to love golf to enjoy this surreal title. What The Golf? may take place on the links and use familiar golfing mechanics to aim and power your shot, but it devolves into an acid trip universe of madness from there, with a crazy assortment of objects you need to get onto the green and an endless array of virtual gags that always one-up the craziness of the previous hole. You won't play it every day, but it's fun to pull out every once in a while when you need a break from reality. Oregon TrailThis is the official Oregon Trail game, a modern refresh of the famous educational title from the 1970s and onward. The Apple Arcade version has beautifully updated graphics, 15 playable adventures and a half-dozen new quests based on actual historical events. If you played the game as a kid, this version will feel familiar, but still has enough novelty to be entertaining. But the real joy should come from introducing it to your kids so they can experience history in the palm of their hands. Sayonara Wild HeartsSayonara Wild Hearts is a psychedelic techno rhythm-based arcade game in which you catch hearts while riding your skateboard, motorcycle or magical deer across astral highways. It's narrated by Queen Latifah and features a Tarot-themed plot, though that's not as important as the gorgeous visuals and addictive gameplay. Collect hearts and tarot cards as you race through mystic vistas in Sayonara Wild Hearts.Dave Johnson/InsiderCat Quest IIImagine a classic fantasy-world role-playing game populated with cats — that's Cat Quest in a nutshell. There are lands to explore, treasure chests to open, dogs to do combat with, and more. The game is utterly charming, packed with traditional hack-and-slash adventure with a dollop of kitty adorableness. You can play in story or arcade mode, solo or cooperative. Manifold GardenReminiscent of Portal, Manifold Garden is an addictive puzzle game that challenges you to solve elaborate puzzles. You can move, look, move objects, pull levers, and even manipulate gravity — you can choose which surface in a room is the floor, for example, by walking to a wall and resetting gravity. The game has a distinct M.C. Escher vibe, enhanced not just by the geometry of the spaces, but also by the ever-shifting logic you need to employ to solve the ever more challenging puzzles. Cut the Rope RemasteredA true classic mobile game, Cut the Rope has been re-released in eye-popping 3D. Like Angry Birds, Cut the Rope is built on a simple game mechanic — in this case, cut ropes with a swipe of the screen to release candy into the mouth of a waiting hungry creature. There's a puzzle in each challenge, as you try to maximize the number of stars you hit as the candy falls. Always a good way to kill a few minutes between meetings, this game belongs on everyone's phone.Some games are classics for a reason, like the charming puzzler Cut the Rope.Dave Johnson/InsiderAssemble With CareOne of the most entertaining puzzle games on any platform, Assemble With Care is a charming title that is more than it at first seems. You're tasked with fixing an assortment of gadgets — phones, watches, a music box, and so on — in a colorful animated interface. But the game has lovely narration which adds an extra layer of depth to every repair you perform, and the European setting is quaint and exotic at the same time. Perhaps the game's best attribute is its simplicity. None of the puzzles are especially hard, which means it's a nice diversion when you don't want to think hard enough to play Cut the Rope or Manifold Garden.FantasianWant to step inside an anime? Fantasian is perhaps the best of the Japanese RPGs you can play on your phone. The graphics are gorgeous, built from more than 150 real-world physical dioramas that were painstakingly photographed and enhanced to become the setting for the game. You play a hero with amnesia who slowly learns who he is as he quests with his robot cohorts and battles all manner of bad guys, but that's secondary to the hack-and-slash combat and delicious visuals. Galaga Wars+It's hard to exaggerate the impact that Galaga had on the early arcade game industry, and Galaga Wars+ brings the endless waves of insect-themed aliens to the smaller screen. The action is intense, the graphics are superb, and the gameplay is mindless (in a good way). And while there are a lot of similar mobile games out there, because this one is an Apple Arcade title, it doesn't demand in-page purchases to advance.Fight endless waves of insectoid aliens in Galaga Wars+.Dave Johnson/InsiderThe Pinball WizardWhile some pinball games pride themselves on photorealistic accuracy, The Pinball Wizard goes another way. And it borrows its name from The Who for a very good reason; your pinball machine is actually a dungeon, and the game requires you to fling an actual wizard around to do battle with monsters while you also collect coins and keys. There's a lot going on here, but it's also a fun and virtually endearing, low-stress arcade game that doesn't demand a lot from you aside from timing the bumpers properly. Really Bad Chess+A philosophical cousin to What The Golf?, Really Bad Chess starts the board with a random assortment of pieces. Rather than the traditional starting line, you might have four rooks, three queens or a handful of knights. The graphics aren't remarkable — it would be great if the top-down visuals didn't look like they came from a black and white newspaper in 1975, but this is the game for anyone with a passing interest in the game and a desire to know, "What if I had a whole front line of knights instead of pawns?" The game looks very flat but the chess scenarios are a blast in Really Bad Chess+.Dave Johnson/InsiderOverlandIf you're looking for a game that's a bit more serious — with a decidedly darker theme — then Overland might be just the ticket. This turn-based rogue-like adventure puts you in a post-apocalyptic wasteland where virtually every decision you make is life or death for your character. You can twist and turn the 3D environment to see it from every angle, inspect your surroundings, and take your car westward. The game is surprisingly tense, with a horror movie sense of urgency at every turn.Read the original article on Business Insider.....»»

Category: topSource: businessinsiderMay 20th, 2022

"Warning lights flashing": the US military is offering record amounts of cash to head off a recruiting crisis

The US military is using record-level enlistment and retention bonuses to attract and keep troops, and those bonuses continue to increase. US Marine Corps recruits do crunches at Marine Corps Recruit Depot San Diego, February 19, 2016.Lance Cpl. Angelica Annastas US military recruiting faces major headwinds as troops leave service and a tight job market lures away potential recruits. The services are using record-level enlistment and retention bonuses to attract and keep troops, and those bonuses continue to increase. Hints that the armed services might soon face a problem keeping their ranks full began quietly, with officials spending the last decade warning that a dwindling slice of the American public could serve.Only about one-quarter of young Americans are even eligible for service these days, a shrinking pool limited by an increasing number of potential recruits who are overweight or are screened out due to minor criminal infractions, including the use of recreational drugs such as marijuana.But what had been a slow-moving trend is reaching crisis levels, as a highly competitive job market converges with a mass of troops leaving as the coronavirus pandemic subsides, alarming military planners.Read Next: Medical Forces Could Be Shorthanded During War Due to Planned Cuts, Milley Says"Not two years into a pandemic, and we have warning lights flashing," Maj. Gen. Ed Thomas, the Air Force Recruiting Service commander, wrote in a memo — leaked in January — about the headwinds his team faces.For now, the services are leaning on record-level enlistment and retention bonuses meant to attract and keep America's military staffed and ready — bonuses that continue to climb.In an interview with Military.com last month, Thomas didn't mince words. He knows he is competing against the private sector to hire people, from technology giants to regional gas stations."If you want to work at Buc-ee's along I-35 in Texas, you can do it for [a] $25-an-hour starting salary," Thomas said. "You can start at Target for $29 an hour with educational benefits. So you start looking at the competition: Starbucks, Google, Amazon. The battle for talent amidst this current labor shortage is intense."Trainees at the 120th Adjutant General Battalion at Fort Jackson in South Carolina, October 30, 2019.Alexandra Shea/Fort Jackson Public AffairsPaired with those competitive offers for workers are a large number of service members retiring, some having delayed leaving the ranks during a pandemic that saw huge instability in the job market.Since fiscal 2020, the US Department of Labor's Veterans' Employment and Training Service — known as VETS — has anticipated that around 150,000 service members would transition out of the military annually as part of its budget justification documents.But in 2020, the Transition Assistance Program, or TAP, the congressionally mandated classes that prepare troops for life outside the military, helped counsel 193,968 service members on their way out of the military, said Lisa Lawrence, a Pentagon spokesperson. That's nearly one-third more newly minted veterans than the Labor Department had planned for.In 2021, that number grew to 196,413. Prior to 2020, the Department of Defense did not report the total number of TAP-eligible service members transitioning, although Lawrence said the number has been somewhere between 190,000 and 200,000 annually in recent years.Payouts aimed at attracting new service members to replace those outgoing veterans are at all-time highs. The Army started offering recruiting bonuses of up to $50,000 in January, and last month the Air Force began promoting up to $50,000 — the most it can legally offer — for certain career fields.The Navy followed with its offer of $25,000 to those willing to ship out in a matter of weeks. It says the bonuses are the result of an "unprecedentedly competitive job market."Cmdr. Dave Benham, a spokesman for the sea service's recruiting command, told Military.com in a recent phone interview that "the private sector is doing things we haven't seen them do before to try and attract talent, so we have to stay competitive."Benham said the scope of the Navy's offer — a minimum of $25,000 to ship out before June — has "never happened before to anybody's collective knowledge around here."Courting and paying for talentUS Army recruits training at Fort Benning.Barry Williams/Getty ImagesThe pandemic economy has placed private-sector workers in the driver's seat, pushing employers to offer more lucrative incentives such as better benefits, flexible work-from-home schedules or massive signing bonuses to make hires. That is putting major pressure on the military as it tries to attract recruits who may be considering the civilian job market.It's all been complicated by the military's myriad of other difficulties getting new troops in the door, such as recruiting efforts quashed by the pandemic, a shrinking pool of eligible recruits, and social media silos complicating advertising.And amid public scandals, such as the 2020 murder of Vanessa Guillén and suicides on the aircraft carrier USS George Washington, military service may seem like a less attractive choice for young Americans."This is arguably the most challenging recruiting year since the inception of the all-volunteer force," Lt. Gen. David Ottignon, the Marine Corps officer in charge of manpower, told the Senate during a public hearing April 27.All of the military's service branches are scrambling to find ways to compete for a younger generation of talent that has plenty of employment opportunities."The military provides a wonderful option for young people, but it's not the only option and so recruiters, I think just like other employers, are trying to understand what the different options are for young people and to address those effectively," said Joey Von Nessen, an economics professor at the University of South Carolina.The bonuses that serve as one of the most immediately tangible lures for new recruits, while escalating, aren't uniform across or even within the services.Most of the bonuses offered for new Air Force recruits range around $8,000 for certain career fields. But for two of the most dangerous jobs, Special Warfare operations and explosive ordnance disposal, the service is making its maximum allowed offer of $50,000 for people to join."It is necessary. I think these are two of our hardest career fields to recruit toward," said Col. Jason Scott, chief of operations for the Air Force Recruiting Service. "It is absolutely necessary to do $50,000 for each of those, and actually $50,000 is the highest initial enlistment bonus amount that we can give."New Marine Corps recruits make their initial phone calls home at Marine Corps Recruit Depot San Diego, May 21, 2018.US Marine Corps/Lance Cpl. Christian M. GarciaOverall, the Air Force is dedicating $31 million to recruiting bonuses in 2022, nearly double what was originally planned for.The Army faces the same problem — and is putting up the same big offers."We're in a search for talent just like corporate America and other businesses; almost everyone has the same issue the military does right now," Maj. Gen. Kevin Vereen, head of US Army Recruiting Command, told Military.com. "We're trying to match incentives for what resonates. For example, financial incentives. Nobody wants to be in debt, so we're offering sign-up bonuses at a historic rate."We've never offered $50,000 to join the Army," he added.In addition to the sign-on bonuses, the Army is also offering new recruits their first duty station of choice — an unprecedented move as new soldiers are typically placed at random around the world. New recruits can choose locations such as Alaska, Fort Drum in New York, and Fort Carson in Colorado."Youth today want to make their own decisions. We're letting them do that," Vereen said.The services are also trying to keep troops from leaving, knowing that a raft of employment opportunities are available for them if they get fed up with military life.The Army, Air Force and Navy have all announced reenlistment bonuses for certain career fields and specialties, some of them in the six-figure range.The Air Force is offering up to $100,000 reenlistment bonuses based on experience and career field. The Navy is also offering those incentives, with fields such as network cryptologists and nuclear technicians making anywhere from $90,000 to $100,000. The Army is offering a more modest cap of $81,000 to reenlist for some jobs.Anecdotally, military families are describing on social media an inability to find open slots for TAP's sessions. Each in-person class is generally limited to 50 people, but Lawrence, the Pentagon spokesperson, denied the program is being overwhelmed since classes are also available in live online, on-demand or hybrid formats.The urgency described by leaders who are putting their money toward keeping skilled service members is a sign of the worry about a brain drain.Unlike the broader enlistment bonuses, many military career fields don't offer cash for reenlistment, and some of these incentives existed prior to the pandemic. But the job market has put pressure on the services to pay up to keep service members in the force.Overweight and hard to reachUS Navy recruits march in formation at Recruit Training Command in Great Lakes, Illinois, May 14, 2020.US Navy/Seaman Amy JohnsonThe military's difficulties attracting recruits go far beyond making the right bonus offer. The forces working against recruiting increased during the grinding global pandemic — lockdowns kept recruiters home and young Americans are refusing vaccines, for example — and are also rooted in longer-term societal shifts in physical fitness and communication."The aggregate effects of two years of COVID is that is two years of not being in high school classrooms, two years of not having air shows and major public events like being in those public spaces, where our potential applicants or potential recruits are getting personal exposure, face-to-face relationships with military recruiters," Thomas said.Only about 40% of Americans who are of prime recruiting age are vaccinated against the virus. Outright refusal to get the shot immediately precludes joining the force and short-circuits any pitch from recruiters. COVID vaccines are among at least a dozen inoculations mandated by the Defense Department."Seventeen-to-24-year-olds are not getting vaccinated, and those [are] people we aren't having a conversation with," Vereen said.Even when potential recruits are interested and big bonuses motivate them to sign on the dotted line, only about 23% of young Americans are even eligible for service.Past legal run-ins or a drug history prevent potential recruits from joining, and more and more Americans are overweight. According to the Centers for Disease Control and Prevention, 40% of adults aged 20 to 39 are obese. That problem has been deemed a national security risk by some because it causes an increasingly shallow pool of potential recruits.The confluence of challenges has others loudly alerting the public that there's a problem.Sen. Thom Tillis, R-North Carolina, the ranking member of the Senate Armed Services Committee personnel panel, says the military is on the cusp of a recruiting crisis.Marine recruits line up for chow.Sgt. Dana Beesley/US Marine Corps"To put it bluntly, I am worried we are now in the early days of a long-term threat to the all-volunteer force. [There is] a small and declining number of Americans who are eligible and interested in military service," Tillis said during an April 27 hearing.He added that "every single metric tracking the military recruiting environment is going in the wrong direction." Just 8% of young Americans have seriously considered joining the military, while only 23% are eligible to enlist, according to Tillis.Meanwhile, the prime demographic for recruiting — 17-to-24-year-olds — is getting harder to reach. The military is running high production value recruiting ads on TV, but most younger Americans are watching YouTube, Twitch and other streaming services.On those platforms, ads are dictated by algorithms based on a person's search history, and prime-age viewers may never be exposed to recruiting spots if they don't already have a general interest in the military.The military has relied on Facebook, with its user base that skews much older, and Instagram pointing users to ads based on their existing interests. The Defense Department banned TikTok from government-issued phones in 2019, shutting out Generation Z's social media platform of choice. However, some recruiters have ignored the ban on the Chinese-owned platform, which is seen by some as a security risk."I know a lot of young people are on TikTok and we're not," Vereen said.When the military does get widespread exposure and makes the news, it can be due to scandals such as the slaying of Guillén at Fort Hood, Texas, or other problems that raise questions about safety and the quality of life in the services.Following a wave of suicides and disclosure of a lack of basic amenities such as hot water and ventilation aboard the George Washington, Master Chief Petty Officer Russell Smith, the Navy's top enlisted leader, was asked by a sailor why the service was spending so much on new recruits, specifically mentioning the hefty $25,000 bonus."I gotta use those bonuses to compel something. ... A post-COVID workforce doesn't love the idea that they have to, they actually have to go to work, talk to people, see them face-to-face, exchange ideas and do work," Smith told the crew, according to a Navy-provided transcript. "They would rather phone it in or work from home somehow and, with the military, you just can't do that."US Navy recruits in the galley of the USS Triton barracks at Recruit Training Command.Scott A. Thornbloom/US NavySome sailors said it didn't seem like the service was prioritizing making its current ranks happy or financially incentivizing them to stick around. Smith said the Navy already offers some bonuses to in-demand specialties and that if a particular job doesn't offer one it's because enough of those sailors "love the work that they do ... and when they do, I don't have to use money as leverage."Smith also told the sailor that he "can compel [them] to stay right here for eight years." Most contracts have an inactive period of reserve service built in following the end of active duty that the Navy can tap into."So, you want me finding sailors to come in and relieve you on time," Smith added.The military services hope the new bonuses will overcome all the difficulties and that they will meet recruiting goals for the year. But the numbers are not encouraging so far.The Army has an uphill climb for the rest of the year, having recruited just 23% of its target in the first five months of the fiscal year.The Navy said that, in order to reach its recruiting goal this year, it will have to reduce the delayed-entry program — allowing someone to enlist before they plan on actually shipping out — to below "historic norms," which could in turn cause recruiting issues in future years.There's likely no relief in sight, according to experts.US population demographics are going in the wrong direction and will make the recruiting job increasingly hard. The millennial and Gen-Z generations are smaller than previous generations, meaning there is a dwindling workforce to pull from. And only a small percentage of those youths appear likely to meet the physical qualifications to join in the first place."I think it's likely that the labor shortage is going to be long-lasting," Von Nessen said. "This is not a short-term phenomenon. It was exacerbated by the pandemic, but it wasn't created by the pandemic exclusively."— Thomas Novelly can be reached at thomas.novelly@military.com. Follow him on Twitter @TomNovelly.— Konstantin Toropin can be reached at konstantin.toropin@military.com. Follow him on Twitter @ktoropin.— Steve Beynon can be reached at Steve.Beynon@military.com. Follow him on Twitter @StevenBeynon.— Rebecca Kheel can be reached at rebecca.kheel@military.com. Follow her on Twitter @reporterkheel.Related: Space Force Offering Bonuses Up to $20,000 for New Guardians with Tech BackgroundsRead the original article on Business Insider.....»»

Category: topSource: businessinsiderMay 19th, 2022

These Are The Ten Biggest Scientific And Control Equipment Companies

Scientific and control equipment is a massive industry that serves as a backbone for many industries, including pharma, food manufacturing, networking, diagnostics and more. The industry has been rearranging its operations after the coronavirus pandemic, and the growth in research & development is expected to drive the industry growth going forward. However, the rising compliance […] Scientific and control equipment is a massive industry that serves as a backbone for many industries, including pharma, food manufacturing, networking, diagnostics and more. The industry has been rearranging its operations after the coronavirus pandemic, and the growth in research & development is expected to drive the industry growth going forward. However, the rising compliance issues could hamper the growth of the industry. Let’s take a look at the ten biggest scientific and control equipment companies. if (typeof jQuery == 'undefined') { document.write(''); } .first{clear:both;margin-left:0}.one-third{width:31.034482758621%;float:left;margin-left:3.448275862069%}.two-thirds{width:65.51724137931%;float:left}form.ebook-styles .af-element input{border:0;border-radius:0;padding:8px}form.ebook-styles .af-element{width:220px;float:left}form.ebook-styles .af-element.buttonContainer{width:115px;float:left;margin-left: 6px;}form.ebook-styles .af-element.buttonContainer input.submit{width:115px;padding:10px 6px 8px;text-transform:uppercase;border-radius:0;border:0;font-size:15px}form.ebook-styles .af-body.af-standards input.submit{width:115px}form.ebook-styles .af-element.privacyPolicy{width:100%;font-size:12px;margin:10px auto 0}form.ebook-styles .af-element.privacyPolicy p{font-size:11px;margin-bottom:0}form.ebook-styles .af-body input.text{height:40px;padding:2px 10px !important} form.ebook-styles .error, form.ebook-styles #error { color:#d00; } form.ebook-styles .formfields h1, form.ebook-styles .formfields #mg-logo, form.ebook-styles .formfields #mg-footer { display: none; } form.ebook-styles .formfields { font-size: 12px; } form.ebook-styles .formfields p { margin: 4px 0; } Get The Full Henry Singleton Series in PDF Get the entire 4-part series on Henry Singleton in PDF. Save it to your desktop, read it on your tablet, or email to your colleagues (function($) {window.fnames = new Array(); window.ftypes = new Array();fnames[0]='EMAIL';ftypes[0]='email';}(jQuery));var $mcj = jQuery.noConflict(true); Q1 2022 hedge fund letters, conferences and more Ten Biggest Scientific And Control Equipment Companies We have referred to the latest available revenue figures to rank the ten biggest scientific and control equipment companies. We have only considered Fortune 1000 companies for our list of the ten biggest scientific and control equipment companies. Below are the ten biggest scientific and control equipment companies: Mettler-Toledo International (>$3 billion) Founded in 1991 and headquartered in Columbus, Ohio, this company offers precision instruments and services for use in industrial, packaging, logistics, laboratory and food retailing applications. Mettler-Toledo International Inc. (NYSE:MTD) shares are down almost 27% YTD and over 1% in the last one year. The company reported a net income of more than $750 million in 2021 and over $600 million in 2020. PRA Health Sciences (>$3 billion) Founded in 1976 and headquartered in Raleigh, N.C., this company offers outsourced development and commercialization services to biotechnology, medical devices and pharmaceutical industries. PRA Health Sciences is a private company that reported a net income of over $190 million in the last fiscal year. Trimble (>$3.2 billion) Founded in 1978 and headquartered in Sunnyvale, Calif., this company offers positioning technology solutions. Trimble Inc (NASDAQ:TRMB) shares are down over 24% YTD and over 13% in the last one year. Its shares are presently trading around $66, while it has a 52-week range of $59.89 and $96.49. The company reported a net income of more than $490 million in 2021 and over $380 million in 2020. Illumina (>$3.5 billion) Founded in 1998 and headquartered in San Diego, this company offers life science tools and integrated systems for large-scale analysis of genetic variation and function. Illumina, Inc. (NASDAQ:ILMN) shares are down almost 39% YTD and over 38% in the last one year. Its shares are presently trading around $232 while it has a 52-week range of $208.35 and $526.00. The company reported a net income of more than $750 million in 2021 and over $650 million in 2020. Keysight Technologies (>$4 billion) Founded in 1937 and headquartered in Santa Rosa, Calif., this company offers electronic design and test solutions to electronics systems, communications, networking and electronics industries. Keysight Technologies Inc (NYSE:KEYS) shares are down almost 34% YTD and over 2% in the last one year. Its shares are presently trading around $136, while it has a 52-week range of $127.93 and $209.08. The company reported a net income of more than $890 million in 2021 and over $600 million in 2020. Ametek (>$5 billion) Founded in 1930 and headquartered in Berwyn, Pa., this company makes electronic instruments and electromechanical devices. AMETEK, Inc. (NYSE:AME) shares are down almost 18% YTD and almost 10% in the last one year. Its shares are presently trading around $121, while it has a 52-week range of $118.28 and $148.07. The company reported a net income of more than $950 million in 2021 and over $850 million in 2020. Agilent Technologies (>$5 billion) Founded in 1999 and headquartered in Santa Clara, Calif., this company offers application focused solutions for life sciences, diagnostics, and applied chemical companies. Agilent Technologies Inc (NYSE:A) shares are down over 25% YTD and over 8% in the last one year. Its shares are presently trading around $118, while it has a 52-week range of $112.64 and $179.57. The company reported a net income of more than $1.20 billion in 2021 and over $700 million in 2020. Roper Technologies (>$5 billion) Founded in 1981 and headquartered in Sarasota, Fla., this company offers engineered products and solutions for the global niche markets. Roper Technologies Inc (NYSE:ROP) shares are down almost 13% YTD and almost 1% in the last one year. Its shares are presently trading around $430 while it has a 52-week range of $417.54 and $505. The company reported a net income of more than $980 million in 2021 and over $800 million in 2020. Avantor (>$6 billion) Founded in 1904 and headquartered in Radnor, Pa., this company offers materials, equipment, instrumentation, and specialty procurement to companies in biopharma, healthcare, education, and applied materials industries. Avantor Inc (NYSE:AVTR) shares are down almost 29% YTD and almost 3% in the last one year. The company reported a net income of more than $570 million in 2021 and over $110 million in 2020. Thermo Fisher Scientific (>$25 billion) Founded in 1960 and headquartered in Waltham, Mass., this company offers analytical instruments, equipment, software and services for supporting research, analysis, discovery, and diagnostics. Thermo Fisher Scientific Inc. (NYSE:TMO) shares are down almost 19% YTD but are up over 19% in the last one year. The company reported a net income of more than $7.70 billion in 2021 and over $6.30 billion in 2020. Updated on May 16, 2022, 11:34 am (function() { var sc = document.createElement("script"); sc.type = "text/javascript"; sc.async = true;sc.src = "//mixi.media/data/js/95481.js"; sc.charset = "utf-8";var s = document.getElementsByTagName("script")[0]; s.parentNode.insertBefore(sc, s); }()); window._F20 = window._F20 || []; _F20.push({container: 'F20WidgetContainer', placement: '', count: 3}); _F20.push({finish: true});.....»»

Category: blogSource: valuewalkMay 16th, 2022

Regulus (RGLS) Up as FDA Accepts IND for Kidney Disease Drug

The FDA accepts Regulus' (RGLS) IND application for RGLS8429 to treat autosomal dominant polycystic kidney disease. The company plans to begin a phase I study in second-quarter 2022. Stock up. Regulus Therapeutics Inc. RGLS announced that the FDA has accepted the investigational new drug (“IND”) application for its novel pipeline candidate, RGLS8429, seeking approval to begin clinical studies on the same for the treatment of autosomal dominant polycystic kidney disease (“ADPKD”).The company plans to initiate a phase I study evaluating RGLS8529 in healthy volunteers for treating ADPKD later in the second quarter of 2022.Shares of Regulus were up 54.8% following the announcement of the news on Wednesday. The stock has lost 15.6% so far this year compared with the industry’s decline of 26.8%.Image Source: Zacks Investment ResearchA phase I single-ascending dose study will assess the safety, tolerability and pharmacokinetics of RGLS8429 in healthy volunteers. After this study, Regulus intends to begin a phase Ib multiple-ascending dose study in adult patients with ADPKD.The company plans to report data from the healthy volunteer study and start dosing patients with ADPKD during the second half of 2022.Per the press release, in the United States, around 140,000 individuals are diagnosed with ADPKD, with an estimated four to seven million affected worldwide. Hence if successfully developed and upon potential approval, RGLS8429 may offer a transformative treatment option for the given patient population.Apart from RGLS8429, Regulus is developing another pipeline candidate, lademirsen (RG-012), for the treatment of adult patients with Alport syndrome, an inherited form of kidney disease.The company, under its collaboration with French pharma giant, Sanofi SNY, announced the completion of enrollment in the phase II HERA study evaluating lademirsen for treating Alport syndrome in February 2022.In November 2018, Regulus transitioned development responsibilities for RG-012 to Genzyme, a subsidiary of Sanofi. SNY bears all costs for the development of lademirsen.RGLS currently has no approved product in its portfolio. Therefore, the successful development of its pipeline candidates remains in key focus for the company.Zacks Rank & Other Stocks to ConsiderRegulus currently carries a Zacks Rank #2 (Buy). Other stocks worth considering in the same sector include Onconova Therapeutics, Inc. ONTX and Soleno Therapeutics, Inc. SLNO, both carrying the same Zacks Rank #2 at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.Onconova Therapeutics’ loss per share estimates have narrowed 22.4% for 2022 and 18.2% for 2023 over the past 60 days.Earnings of Onconova Therapeutics have surpassed estimates in each of the trailing three quarters. ONTX delivered an earnings surprise of 22.72% on average.Soleno Therapeutics’ loss per share estimates have narrowed 9.1% for 2022 and 25.9% for 2023 over the past 60 days.Earnings of Soleno Therapeutics have surpassed estimates in two of the trailing four quarters, met the same once and missed the same on the other occasion. SLNO delivered an earnings surprise of -10.92%, on average. Just Released: Zacks Top 10 Stocks for 2022 In addition to the investment ideas discussed above, would you like to know about our 10 top buy-and-hold tickers for the entirety of 2022? Last year's 2021 Zacks Top 10 Stocks portfolio returned gains as high as +147.7%. Now a brand-new portfolio has been handpicked from over 4,000 companies covered by the Zacks Rank. Don’t miss your chance to get in on these long-term buysAccess Zacks Top 10 Stocks for 2022 today >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Sanofi (SNY): Free Stock Analysis Report Regulus Therapeutics Inc. (RGLS): Free Stock Analysis Report Onconova Therapeutics, Inc. (ONTX): Free Stock Analysis Report Soleno Therapeutics, Inc. (SLNO): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research.....»»

Category: topSource: zacksMay 12th, 2022

Pharma ETFs in Focus Post Q1 Earnings

Many industry bigwigs reported solid results with some beating on earnings or revenues or both. The Q1 earnings picture for the healthcare sector seems solid, with results from companies that have reported so far up 17.2% on 15.8% revenue growth. Both earnings and revenue beat ratios also seem impressive, with 79.6% and 74.1%, respectively. Combining the actual results with the estimates for the still-to-report companies, total earnings for the sector are expected to grow 16.8% on revenue growth of 15.7% (see: all the Healthcare ETFs here).Many industry bigwigs reported solid results with some beating on earnings or revenues or both. However, solid earnings failed to impress pharma ETFs over the past month due to a broad sell-off in the market. iShares U.S. Pharmaceuticals ETF IHE, Invesco Dynamic Pharmaceuticals ETF PJP, VanEck Vectors Pharmaceutical ETF PPH, SPDR S&P Pharmaceuticals ETF XPH and First Trust Nasdaq Pharmaceuticals ETF FTXH are down in double digits in a month.Let’s delve deeper into earnings of some of the bigwigs:Earnings in FocusJohnson and JohnsonThe world's biggest healthcare products’ maker continued its long streak of earnings beat, but lagged the revenue estimates. Earnings per share came in at $2.67, beating the Zacks Consensus Estimate by 7 cents but declining 16.8% from the year-ago quarter. Revenues grew 5% year over year to $23.43 billion but fell short of the Zacks Consensus Estimate of $23.74 billion. For 2022, Johnson & Johnson slashed the revenue guidance to $94.8-$95.8 billion from $95.9-$96.9 billion. The earnings per share guidance was also reduced to $10.15-$10.35 from $10.40-$10.60, representing year-over-year growth of 3.6-5.6%.PfizerPfizer also missed on earnings and revenues. Earnings per share of $1.62 were well below the Zacks Consensus Estimate of $1.66. Revenues of $25.66 billion fell short of the consensus mark of $26.49 billion. On a year-over-year basis, earnings and revenues increased 72% and 77%, respectively. The U.S. drug giant maintained its 2022 revenue guidance of $98-$102 billion but lowered the earnings guidance to $6.25-$6.45 from $6.35-$6.55 per share.MerckMerck reported better-than-expected results. Earnings per share of $2.14 outpaced the Zacks Consensus Estimate of $1.81 and increased 84% from the year-ago quarter. Revenues rose 50% year over year to $15.9 billion and came in above the consensus mark of $15 billion. For 2022, Merck lifted the revenue guidance to $$56.9-$58.1 billion from $56.1-$57.6 billion and the earnings guidance to $7.24-$7.36 from $7.12-$7.27 (read: Healthcare ETFs Outperform Amid Rising Uncertainties).Bristol-MyersBristol-Myers reported earnings per share of $1.96, beating the Zacks Consensus Estimate of $1.92 and improving from the year-ago earnings of $1.74. Revenues grew 5% year over year to $11.65 billion and edged past the Zacks Consensus Estimate of $11.26 billion. The company reduced its earnings per share guidance range to $7.44-$7.74 from $7.65-$7.95 for 2022 while expects revenues in line with 2021.Eli LillyEli Lilly came up with robust results. Earnings of $2.62 per share outpaced the Zacks Consensus Estimate of $2.32 but were 63% higher than the year-ago earnings. Revenues climbed 15% to $7.8 billion and surpassed the estimate of 7.52 billion. Eli Lilly raised the 2022 revenue guidance but lowered the earnings guidance. It expects revenues in the range of $28.8-$29.3 billion, up from $27.8-$28.3 billion, while earnings per share are expected between $8.15 and $8.30, down from $8.50 and $8.65.ETF AngleiShares U.S. Pharmaceuticals ETF (IHE)iShares U.S. Pharmaceuticals ETF provides exposure to 45 U.S. companies that manufacture prescription or over-the-counter drugs or vaccines by tracking the Dow Jones U.S. Select Pharmaceuticals Index. The in-focus five firms are the top 10 holdings in the basket, accounting for a combined 60.8% of the total assets, suggesting heavy concentration.iShares U.S. Pharmaceuticals ETF has $379.7 million in AUM and charges 42 bps in fees and expense. Volume is light as it exchanges about 11,000 shares a day. The fund carries a Zacks ETF Rank #3 (Hold) with a High risk outlook.Invesco Dynamic Pharmaceuticals ETF (PJP)Invesco Dynamic Pharmaceuticals ETF offers exposure to companies that are principally engaged in the research, development, manufacture, sale, or distribution of pharmaceuticals and drugs of all types. It follows the Dynamic Pharmaceuticals Intellidex Index and holds 27 stocks in its basket, with the in-focus firms making up for nearly 5% share each.Invesco Dynamic Pharmaceuticals ETF has AUM of about $303.5 million and sees a lower volume of around 18,000 shares a day. The fund charges 58 bps in fees and expenses. The ETF has a Zacks ETF Rank #3 with a High risk outlook.SPDR S&P Pharmaceuticals ETF (XPH)SPDR S&P Pharmaceuticals ETF provides exposure to pharma companies by tracking the S&P Pharmaceuticals Select Industry Index. With AUM of $173.6 million, it trades in a moderate volume of around 76,000 shares a day and charges 35 bps in fees a year (read: 5 Safe ETF Bets to Consider After a Dull Market Last Week).SPDR S&P Pharmaceuticals ETF holds 47 securities, with the in-focus firms making up for nearly 5% share each. It has a Zacks ETF Rank #3 with a High risk outlook.VanEck Vectors Pharmaceutical ETF (PPH)VanEck Vectors Pharmaceutical ETF follows the MVIS US Listed Pharmaceutical 25 Index and holds 25 stocks in its basket. The in-focus five firms account for around 5% share each. The product has amassed $298.8 million in its asset base and trades in a good volume of about 128,000 shares a day. The expense ratio is 0.35%.VanEck Vectors Pharmaceutical ETF carries a Zacks ETF Rank #3 with a Medium risk outlook.First Trust Nasdaq Pharmaceuticals ETF (FTXH)First Trust Nasdaq Pharmaceuticals ETF tracks the Nasdaq US Smart Pharmaceuticals Index, holding 28 securities in its basket. The in-focus five firms account for a combined 30.9% of the assets. FTXH has a lower level of $15.3 million in AUM and an average daily volume of 3,000 shares.First Trust Nasdaq Pharmaceuticals ETF charges 60 bps in annual fees and has a Zacks ETF Rank #3.  Want key ETF info delivered straight to your inbox? Zacks’ free Fund Newsletter will brief you on top news and analysis, as well as top-performing ETFs, each week.Get it free >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Invesco Dynamic Pharmaceuticals ETF (PJP): ETF Research Reports iShares U.S. Pharmaceuticals ETF (IHE): ETF Research Reports SPDR S&P Pharmaceuticals ETF (XPH): ETF Research Reports VanEck Pharmaceutical ETF (PPH): ETF Research Reports First Trust NASDAQ Pharmaceuticals ETF (FTXH): ETF Research Reports To read this article on Zacks.com click here. Zacks Investment Research.....»»

Category: topSource: zacksMay 12th, 2022

Lighting The Gas Under European Feet: How Politicians & Journalists Get Energy So Wrong

Lighting The Gas Under European Feet: How Politicians & Journalists Get Energy So Wrong Authored by Joakim Book via The Mises Institute, “We live in a time where few understand how things get made. It is fine to not know where stuff comes from, but it isn’t fine to not know where stuff comes from while dictating to the rest of us how the economy should be run." - Doomberg Eighty-five percent of human energy usage comes from burning things. Either plants or trees grown in a geologically recent past or plants or trees (and decomposed animals) from ancient times. Solar, wind, hydro, geothermal, etc.—all the things that occupy a climate-conscious citizen, activist, or politician’s dreams—are frizzles around the edges. Human civilization is powered by combustion; human beings are a fossil fuel–burning civilization. You can take away the civilization part, which seems to be the end goal for some environmentalists, but bar that, you can’t take away the fossil fuel part. If we listened only to our energy overlords’ preaching, we would get a very different impression of what the world is like. Wind turbines powering all those electrified vehicles on our roads, solar panels and batteries of immense capacities light and heat our homes. Dirty oil and polluting coal are out; green, clean, and smart machines on the way in. Nothing could be further from the truth. Renewables don’t power our societies, they’re not about to any time soon, and the fact that they’re not isn’t a policy choice—or “greedy capitalism” preventing this utopian (dystopian) vision. First, some housekeeping: Energy is not the same as electricity. Electricity is a secondary energy source, derived from primary energy sources through a conversion process—combustion or turbines spinning. The 85 percent figure above is for energy use. The bombastic figures in the press about the massive growth and expanse of renewables are for electricity, which is only a subset of all the world’s energy use (some 20 percent). Oil, coal, and gas for transport, heating, fertilizers, and construction dwarf the symbolic solar panels governments paid people to place on their roof. Solar panels and wind turbines produce a minor part of the electricity needs, but do nothing to address the larger energy needs. In contrast, fossil fuels are energy-dense, reliable, on-demand sources of either energy or electricity, and we have excelled both at storing and transporting them. Dreams of a green revolution, per the energy theorist Vaclav Smil, were always mirages: We are a fossil-fueled civilization whose technical and scientific advances, quality of life, and prosperity rest on the combustion of huge quantities of fossil carbon, and we cannot simply walk away from this critical determinant of our fortunes in a few decades, never mind years. Instead, suddenly facing an adversary rich in raw materials and fossil fuels, the West’s talking heads doubled down on their green dreams. From behind comfortable newspaper desks, heated and electrified by natural gas, it’s remarkably easy to say things like: “The new reality is that we have to go all the way to universal electrification even faster, powered by 100% renewable energy with green hydrogen filling the gaps” (Andreas Kluth, at Bloomberg). For the New Yorker, John Cassidy recently told us that we must “prevent future Putins from trying to hold the world to energy ransom—at least one worthy outcome of the tragedy that is Ukraine.” In a powerful speech in the middle of the Russia flurry in March, Isabel Schnabel of the Executive Board at the European Central Bank rallied for renewable power: Every solar panel installed, every hydropower plant built and every wind turbine added to the grid are taking us a step closer to energy independence and a greener economy…. Our dependence on fossil energy sources is not only considered a peril to our planet, it is also increasingly seen as a threat to national security and our values of liberty, freedom and democracy. Luckily, Schnabel is in control of nothing less than the Eurozone’s printing press. One-upped by a fellow German, the reality-challenged finance minister Christian Lindner taught us that renewable electricity is “the energy of freedom.” What he failed to understand is that renewable electricity generation in Germany requires boatloads and pipe loads of Russian gas, Russian oil, and Russian commodities: the steel and cement to construct their precious wind towers are made from coal, not even counting the extreme heat needed to shape the steel and iron that makes up its body.  A single wind turbine uses thousands of kilograms of nickel in its shaft and gear, plus some rare earth minerals from some pretty unclean sources. The gigantic structures, hundreds of meters tall and much too clunky to easily transport, are erected and moved there by machines that swallow diesel by the gallon. Fossil fuels are machine food, as Alex Epstein is fond of saying, and nothing drinks petrol like the machines that power a thirsty wind energy industry. When renewable sources are added to the electricity grid in large quantities, the cost of electricity goes up, not down, because their fickle reliance on weather requires them to be backstopped by thermal plants that run on coal or natural gas. The more renewables you add, the more natural gas you need. Actually, Fossil Fuels Aren’t Optional The conclusion from much political and media messaging on climate is the same: burning fossil fuels for energy is a choice, a bad one, and we must choose differently. The moral case against Russia is just a cherry on top. “Would you rather rely on Mr. Putin’s Russia?” The Economist asked in a recent cover story on energy security. The very same Russia that Bloomberg News described as: “a commodities powerhouse, producing and exporting huge amounts of materials the world uses to build cars, transport people and goods, make bread and keep the lights on.” But the writers at The Economist insist: “As the world weans itself off dirty fuels, it must switch to cleaner energy sources.” When we listen to the political overlords in Brussels or Berlin, or the intellectual ones in think tanks, political parties, or at influential media outlets, we get the impression that relying on “Mr. Putin’s Russia” can be done away with—as optional and care-free as picking a different ice cream flavor. To hammer home the “renewable revolutions are impossible” point, let’s use the poster child for renewables, Germany. Here is its energy use over the last half century: Let me know if you can spot Germany’s revolutionary Energiewende in the early 2010s. With a microscope, I can detect a little bit of wind crowding out some nuclear—while gas keeps growing and coal continues its fifty-five-year decline. What sort of fairytale must one believe to think that the purple and yellow shares—almost invisible at the top—could in any way supplant the others, preferably before next winter when Putin’s withholding of gas would once again be disastrous for Europeans. A prominent German think tank, Agora Energiewende, also thinks it’s perfectly possible. Its projections depend, not just on building and installing more wind energy plants than ever before, but raising that rate of construction by about one-third every year for years on end. To describe those plans as “optimistic” somehow doesn’t cut it: The International Energy Agency (IEA), staffed with the same sort of reality-resistant dreamers, produced this wonderful graph that plans for the energy production in a net-zero future (NZE): At great expense and inconvenience, the world can indeed increase its use of solar and wind—but remember: they destabilize grids and constitute a vanishingly small portion of world energy needs. To replace what we need, and accommodate growth for the billions globally who scrape by on a minimum of energy, the IEA says we must add solar and wind capacity at a vertiginous rate, never before achieved, at way faster than their own forecasts. As Alex Epstein writes in the preface to his future book Fossil Future: a net-zero policy, actually implemented “would certainly be the most significant act of mass murder since the killings of one hundred million people by communist regimes in the twentieth century—and it would likely be far greater.” If you believe, as so many politicians, activists, and deluded journalists do, that this is a mere policy decision, you are sadly mistaken. The impossibility of renewables is a technical and physical problem—not an economic, financial, moral, or political problem. Gaslighting Europeans According to mental health site VeryWellMind, gaslighting is “a form of manipulation that often occurs in abusive relationships. It is a covert type of emotional abuse where the bully or abuser misleads the target, creating a false narrative and making them question their judgments and reality. Ultimately, the victim of gaslighting starts to feel unsure about their perceptions of the world and even wonder if they are losing their sanity.” Consider the following combination of expert-led gaslighting:  The entire 2010s and beyond, politicians pooh-poohed nuclear: in words (rallying cries and moral suasion) and actions (strict regulations), they prevented any expansion and shut down capacity. European environmental regulation and climate activists have stopped as much oil and gas extraction as they could. Most countries have banned or otherwise prevented “fracking,” the natural gas extraction method that turned America into an energy exporter. For the last decade and more, climate warriors inside and outside governments have hauled boatloads of cash onto “green” energies—everything from wind and solar to experimental forms of tidal energy. Green electricity sources, because of the unpredictable load that makes them unsuitable for modern civilization, have expanded in consort with natural gas because the dirty secret of the former is that they require rapidly available backup power—for which the latter is the convenient choice. Because all things “carbon” are considered bad, politicians, journalists, and the Greta Thunbergs of the world have done everything in their power to sway more people into putting solar panels on their roofs and electric vehicles in their garages. That strains an already fragile grid by adding more demand and another variable supply: crucially, it requires lots more nickel, palladium, and silver—with Russia among the world’s largest supplier for those key commodities. One would suppose that, on the back of the war in Ukraine, the strict Western sanctions on Russia, and energy prices going through the roof, the green-washed politicians and policymakers who rule our lives would offer excuses. Now that the Russian invasion had those very same policymakers cutting commercial ties to that despicable empire-building strongman, and energy prices and access suddenly rose to the forefront of everyone's mind, we’d expect a bit of humility. Apologies are in order: Fellow Europeans, against market prices, physics, and sanity, we pushed you into worse forms of electricity generation and endangered our energy security. Instead of doing what we should have done, we relied more and more on the commodities exported from countries like Russia. For making Europeans more beholden to Putin, we apologize. Instead, we got gaslighting on a remarkable scale. “Weaning off” Silly The world isn’t weaning itself off fossil fuels—it can’t, and it shouldn’t. More importantly, “cleaner energy” aren’t options on a shopping menu, available as inconsequential choices the way consumers may choose Doritos over Pringles or a new toothpaste. It’s becoming increasingly clear, to more and more people, that withdrawing from fossil fuels “for environmental reasons” is not a choice. A society and a world of 8 billion people more advanced than that powered by a horse and buggy, cannot do without the explosive power of fossil fuels. Tyler Durden Thu, 05/12/2022 - 02:00.....»»

Category: blogSource: zerohedgeMay 12th, 2022

5 Biotech Stocks Set to Outpace Q1 Earnings Estimates

Let us take a look at some drug/biotech stocks, ANGN, APLT, BOLT, IKNA and LABP, which are poised to beat on first-quarter earnings. It has been a mixed earnings season for the drug and biotech sector so far. While several large drug/biotech companies beat estimates for both earnings and revenues, others like Pfizer missed on both counts. Many companies beat estimates for earnings while missing the same for sales or vice versa. Most companies maintained their previously issued financial outlook for 2022. There are some smaller biotechs, which are yet to report.Per the Zacks classification, the pharma/biotech industry comes under the broader Medical sector, which comprises pharma/biotech as well as medical device companies.Per the Earnings Trends report, as of May 4, 77.2% of the companies in the Medical sector, constituting nearly 87.8% of the sector’s market capitalization, reported earnings. While 84.1% of the companies beat earnings estimates, 75% beat the same for revenues. Earnings increased 18.9% year over year on 17.3% higher revenues.Overall, first-quarter earnings of the Medical sector are expected to rise 16.3% on a 14.8% sales increase.Zeroing in on WinnersHere we have highlighted five biotech companies — Angion Biomedica ANGN, Applied Therapeutics APLT, Bolt Biotherapeutics BOLT, Ikena Oncology IKNA and Landos Biopharma LABP — that are expected to deliver a beat in their upcoming quarterly results.Earnings ESP is our proprietary methodology for determining the stocks that have the best chance to deliver an earnings surprise. Earnings ESP shows the percentage difference between the Most Accurate Estimate and the Zacks Consensus Estimate.According to the Zacks model, the combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. The selection can be done with the help of the Zacks Stock Screener.Our research shows that for stocks with this combination, the chance of an earnings surprise is as high as 70%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.5 Drug/Biotech Stocks That Match the CriteriaAngion Biomedica This clinical-stage biotech has an Earnings ESP of +26.44% and a Zacks Rank of 1. You can see the complete list of today’s Zacks #1 Rank stocks hereThe Zacks Consensus Estimate for the first quarter is pegged at a loss of 44 cents per share. Angion Biomedica is expected to release results next week.Angion Biomedica beat estimates in three of the last four quarters while missing in one, with the average surprise being 47.51%Angion Biomedica Corp. Price and EPS Surprise Angion Biomedica Corp. price-eps-surprise | Angion Biomedica Corp. QuoteApplied Therapeutics Also a clinical-stage biotech, Applied Therapeutics makes novel drug candidates against validated molecular targets in indications of high unmet medical needs. APLT has an Earnings ESP of +21.95% and a Zacks Rank of 2. The Zacks Consensus for the first quarter is pegged at a loss of 82 cents per share.Applied Therapeutics beat estimates in two of the last four quarters while missing in one and delivering in-line results in one. The company’s average earnings surprise is 2.58%. The company should release results this month.Applied Therapeutics Inc. Price and EPS Surprise Applied Therapeutics Inc. price-eps-surprise | Applied Therapeutics Inc. QuoteBolt Biotherapeutics This Redwood City, CA-based immuno-oncology biotech, Bolt Biotherapeutics has an Earnings ESP of +2.13% and a Zacks Rank of #3. The Zacks Consensus Estimate for the first quarter is pegged at a loss of 71 cents per share.Bolt Biotherapeutics missed estimates in three of the last four quarters while delivering in-line results in one with the average negative earnings surprise being 28.35%.Bolt Biotherapeutics, Inc. Price and EPS Surprise Bolt Biotherapeutics, Inc. price-eps-surprise | Bolt Biotherapeutics, Inc. QuoteIkena Oncology Boston-based cancer biotech, Ikena Oncology has an Earnings ESP of +4.14% and a Zacks Rank of 2. The Zacks Consensus Estimate for the first quarter is pegged at a loss of 42 cents per share.Ikena Oncology beat earnings estimates in two of the last four quarters while missing in the other two with the average negative surprise being 33.37%.Ikena Oncology, Inc. Price and EPS Surprise Ikena Oncology, Inc. price-eps-surprise | Ikena Oncology, Inc. QuoteLandos Biopharma Landos Biopharma is a clinical biotech focused on developing novel oral therapeutics for autoimmune diseases. The company has an Earnings ESP of +4.70% and a Zacks Rank #2. The Zacks Consensus Estimate for the first quarter is pegged at a loss of 37 cents per share.Landos Biopharma beat estimates in two of the last four quarters while missing in one and delivering in-line results in one. The company’s average earnings surprise is 34.91%.Landos Biopharma, Inc. Price and EPS Surprise Landos Biopharma, Inc. price-eps-surprise | Landos Biopharma, Inc. QuoteStay on top of upcoming earnings announcements with the Zacks Earnings Calendar. Special Report: The Top 5 IPOs for Your Portfolio Today, you have a chance to get in on the ground floor of one of the best investment opportunities of the year. As the world continues to benefit from an ever-evolving internet, a handful of innovative tech companies are on the brink of reaping immense rewards - and you can put yourself in a position to cash in. One is set to disrupt the online communication industry. Brilliantly designed for creating online communities, this stock is poised to explode when made public. With the strength of our economy and record amounts of cash flooding into IPOs, you don’t want to miss this opportunity.>>See Zacks’ Hottest IPOs NowWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Angion Biomedica Corp. (ANGN): Free Stock Analysis Report Applied Therapeutics Inc. (APLT): Free Stock Analysis Report Landos Biopharma, Inc. (LABP): Free Stock Analysis Report Bolt Biotherapeutics, Inc. (BOLT): Free Stock Analysis Report Ikena Oncology, Inc. (IKNA): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research.....»»

Category: topSource: zacksMay 11th, 2022

Drug/Biotech Stocks" Q1 Earnings on May 10: EXEL, BHC & More

Let's look at the five biotech/drug companies that are slated to release quarterly results on May 10. As we approach the end of the earnings season, several drug/biotech companies have already reported their quarterly results. Overall, results of the said sector were mixed.Per the Zacks classification, the pharma/biotech industry comes under the broader Medical sector, which comprises pharma/biotech and generic companies, as well as medical device companies.Per the Earnings Trends report, as of May 4, 77.2% of companies in the Medical sector, constituting nearly 87.8% of the sector’s market capitalization, have reported earnings. While 84.1% of the companies beat earnings estimates, 75% beat the same for revenues. Earnings increased 18.9% year over year on 17.3% higher revenues.Overall, first-quarter earnings of the Medical sector are expected to rise 16.3% on a 14.8% sales increase.Let's see how things have shaped up for Bausch Health Companies Inc. BHC, Exelixis, Inc. EXEL, Reata Pharmaceuticals, Inc. RETA, Epizyme, Inc. EPZM and Catalyst Pharmaceuticals, Inc. CPRX in the first quarter. These companies will report earnings on May 10:Bausch Health Companies Inc.Bausch’s earnings surpassed the Zacks Consensus Estimate in each of the trailing four quarters, delivering a beat of 8.95%, on average. In the last-reported quarter, the company had delivered an earnings surprise of 17.59%.Bausch has an Earnings ESP of 0.00% and a Zacks Rank #3. The Zacks Consensus Estimate for first-quarter earnings is $1.03 per share. You can see the complete list of today’s Zacks Rank #1 (Strong Buy) stocks here.Per our proven model, stocks with the combination of a positive Earnings ESP and a Zacks Rank #1, #2 (Buy) or #3 (Hold) have a good chance of delivering an earnings beat. This does not seem to be the case with Bausch for the to-be-reported quarter. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.Bausch’s leading brands performed well in the last-reported quarter, and the momentum is likely to have continued in the first quarter.Salix segment revenues increased year over year in the last-reported quarter, a trend that most likely continued in the to-be reported quarter.Revenues from International Rx, Ortho Dermatologics and the Diversified Products segments declined on a yearly basis in the last-reported quarter. It remains to be seen whether the trend continued in the first quarter.Bausch Health Cos Inc. Price and EPS Surprise Bausch Health Cos Inc. price-eps-surprise | Bausch Health Cos Inc. QuoteExelixis, Inc.Exelixis’ earnings surpassed estimates in two of the trailing four quarters and missed the same on the other two occasions, delivering a beat of 169.36%, on average. In the last-reported quarter, the company delivered an earnings surprise of 314.29%.Our proven model predicts an earnings beat for Exelixis in the to-be-reported quarter. Exelixis’ Earnings ESP is +21.95% and it has a Zacks Rank #3 currently. The Zacks Consensus Estimate for its earnings in the to-be-reported quarter stands at 14 cents.Exelixis’ first-quarter 2022 revenues are likely to have been driven by the sales of Cabometyx, which is approved for advanced renal-cell carcinoma and previously treated hepatocellular carcinoma.Exelixis, Inc. Price and EPS Surprise Exelixis, Inc. price-eps-surprise | Exelixis, Inc. QuoteReata Pharmaceuticals, Inc.Reata’s earnings surpassed estimates in three of the trailing four quarters and missed the same on the other occasion, delivering a beat of 8.54%, on average. In the last-reported quarter, the company delivered an earnings surprise of -1.73%.Reata has an Earnings ESP of 0.00% and a Zacks Rank #3. The Zacks Consensus Estimate for its loss in the to-be-reported quarter stands at $2.26 per share.Reata currently has two pivotal-stage pipeline candidates — bardoxolone and omaveloxolone. The company submitted a new drug application for omaveloxolone as a treatment for Friedreich's ataxia in March 2022.Reata’s top line currently comprises of collaboration revenues, which declined substantially in the last-reported quarter — a trend that most likely continued in the first quarter.Operating expenses are likely to have increased in the to-be reported quarter owing to the developmental activities related to its pipeline candidates.Reata Pharmaceuticals, Inc. Price and EPS Surprise Reata Pharmaceuticals, Inc. price-eps-surprise | Reata Pharmaceuticals, Inc. QuoteEpizyme, Inc.Epizyme’s earnings missed estimates in each of the trailing four quarters, delivering an earnings surprise of -22.49%, on average. In the last-reported quarter, the company delivered an earnings surprise of -19.51%.Epizyme has an Earnings ESP of 0.00% and a Zacks Rank #3. The Zacks Consensus Estimate for its earnings in the to-be-reported quarter stands at a loss of 35 cents per share.The company’s lead drug, Tazverik (tazemetostat) continues to perform well. Epizyme’s first-quarter 2022 revenues are likely to have been driven by the sales of Tazverik, which is approved for treating follicular lymphoma and epithelioid sarcoma.Epizyme, Inc. Price and EPS Surprise Epizyme, Inc. price-eps-surprise | Epizyme, Inc. QuoteCatalyst Pharmaceuticals, Inc.Catalyst’s earnings surpassed estimates in two of the trailing four quarters, met the same once and missed the same on the other occasion, delivering a surprise of 18.75%, on average. In the last-reported quarter, the company delivered an earnings surprise of -25.00%.Catalyst has an Earnings ESP of 0.00% and a Zacks Rank #3. The Zacks Consensus Estimate for its earnings in the to-be-reported quarter stands at 14 cents per share.The uptake of the company’s lead drug, Firdapse (amifampridine), has been encouraging so far. Catalyst’s first-quarter 2022 revenues are likely to have been driven by the sales of Firdapse which is approved for treating Lambert-Eaton myasthenic syndrome.Firdapse sales grew both sequentially as well as year over year in the last-reported quarter — a trend that most likely continued in the first quarter.Catalyst Pharmaceuticals, Inc. Price and EPS Surprise Catalyst Pharmaceuticals, Inc. price-eps-surprise | Catalyst Pharmaceuticals, Inc. QuoteStay on top of upcoming earnings announcements with the Zacks Earnings Calendar. 7 Best Stocks for the Next 30 Days Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers "Most Likely for Early Price Pops." Since 1988, the full list has beaten the market more than 2X over with an average gain of +25.4% per year. So be sure to give these hand-picked 7 your immediate attention. See them now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Exelixis, Inc. (EXEL): Free Stock Analysis Report Catalyst Pharmaceuticals, Inc. (CPRX): Free Stock Analysis Report Epizyme, Inc. (EPZM): Free Stock Analysis Report Reata Pharmaceuticals, Inc. (RETA): Free Stock Analysis Report Bausch Health Cos Inc. (BHC): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research.....»»

Category: topSource: zacksMay 9th, 2022

Amarin (AMRN) Q1 Earnings & Sales Hurt by Vascepa Generics

Amarin's (AMRN) Vascepa sales decline year over year amid rising generic competition and COVID-related disruptions during the first quarter. The company's stock falls significantly on May 4. Amarin Corporation PLC AMRN reported first-quarter 2022 adjusted loss of 6 cents (excluding stock-based compensation) per American depositary share against adjusted earnings of 3 cents in the year-ago period. The Zacks Consensus Estimate was pegged at earnings of 2 cents.Revenues, primarily from its cardiovascular drug, Vascepa, were down almost 33% year over year to approximately $94.6 million in the quarter, missing the Zacks Consensus Estimate of $127.91 million. Sales were hurt due to rising generic competition in the United States as well as lower net prices in certain countries.The company continues to avoid revenue guidance for 2022 due to the uncertainty related to the COVID-19 pandemic and generic competition for its sole marketed drug, Vascepa, in the United States.Shares of Amarin crashed 43.1% on May 4 on lackluster first-quarter results and also most probably on the increasing unfavorable impact of generics on Vascepa sales in the United States. The stock has declined 53.7% so far this year compared with the industry’s 21.2% decrease.Image Source: Zacks Investment ResearchQuarter in DetailsProduct revenues, entirely from Vascepa, were $94 million, down approximately 34% year over year due to lower volumes in the United States amid rising generic competition for Vascepa’s reduction of triglyceride levels indication. The company stated that a new generic version entered the U.S. market during the first quarter, taking the total to three generics versions of Vascepa. Moreover, Vascepa sales were also hurt due to ongoing challenges related to COVID-19 disruptions.Licensing revenues were $0.6 million in the first quarter compared with $0.8 million in the year-ago period. The royalty revenues were primarily from sales of Vascepa recorded by its partners in Canada, the China region and the Middle East. Initial sales of the drug in Germany were unfavorably impacted during the first quarter due to a significant surge in COVID-19 cases in the country.The company ended the quarter with $389.3 million in cash and investments, compared with $489.1 million as of Dec 31, 2021.Vascepa UpdateIn October 2021, Amarin initiated a new Go-To-Market strategy in the United States that focuses on enhancing awareness and expanding the company’s reach to healthcare providers, increasing managed care access for Vascepa, and prioritizing cardiovascular risk reduction indication. The company continues to progress with its strategy and focuses on stabilizing Vascepa revenues. It also expanded coverage for Vascepa to approximately 45% of total commercial and Medicare Part D lives.Amarin launched Vazkepa (U.S. tradename Vascepa) in Germany in September last year. The company received reimbursement decisions in up to eight European countries and plans to launch the drug in six of them in 2022.Apart from Europe, Amarin is also focusing on expanding in other international countries. The company’s partners are expected to gain approval for Vascepa and launch it in up to six new countries this year.The company’s partner gained approval for Vascepa in Hong Kong recently and  is planning to launch the drug later this year. A regulatory application seeking approval for Vascepa is under review in China.Amarin Corporation PLC Price, Consensus and EPS Surprise Amarin Corporation PLC price-consensus-eps-surprise-chart | Amarin Corporation PLC QuoteZacks Rank & Stock to ConsiderAmarin currently carries a Zacks Rank #3 (Hold).Some better-ranked stocks from the pharma/biotech sector include Alkermes ALKS, Deciphera Pharmaceuticals DCPH and BeiGeneBGNE. While Alkermes sports a Zacks Rank #1 (Strong Buy), Deciphera and BeiGene carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.Alkermes’ loss per share estimates have improved from 14 cents to 3 cents for 2022 in the past 60 days. ALKS has gained 24.4% so far this year.Alkermes delivered an earnings surprise of 350.48%, on average, in the last four quarters.Estimates for Deciphera have narrowed from a loss of $2.94 to $2.77 for 2022 in the past 60 days. DCPH has risen 10.2% so far this year.Deciphera delivered a negative earnings surprise of 2.73%, on average, in the last four quarters.BeiGene’s loss per share estimates have narrowed from $15.79 to $15.66 for 2022 in the past 60 days. BGNE has declined 39.8% so far this year.BeiGene delivered an earnings surprise of 14.63%, on average, in the last four quarters. Zacks Names "Single Best Pick to Double" From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all. It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time. This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.Free: See Our Top Stock and 4 Runners Up >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Alkermes plc (ALKS): Free Stock Analysis Report Amarin Corporation PLC (AMRN): Free Stock Analysis Report BeiGene, Ltd. (BGNE): Free Stock Analysis Report Deciphera Pharmaceuticals, Inc. (DCPH): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research.....»»

Category: topSource: zacksMay 5th, 2022

Moderna (MRNA) Beats on Q1 Earnings, to Start Two Late Studies

Moderna's (MRNA) Spikevax sales beat expectations. The company plans to start late-stage studies for Omicron-containing bivalent booster and seasonal flu vaccines later this year. Stock gains in pre-market. Moderna Inc. MRNA reported earnings of $8.58 per share for the first quarter of 2022, comfortably beating the Zacks Consensus Estimate of $5.18. The company had reported earnings of $2.84 per share in the year-ago quarter. The significant improvement in the bottom line was driven by strong year-over-year growth in revenues.Revenues in the quarter were $6.1 billion, significantly beating the Zacks Consensus Estimate of $4.50 billion. In the year-ago quarter, revenues were $1.93 billion. The significant increase in revenues was driven by the strong sales of its COVID-19 vaccine, Spikevax, and its booster doses.Moderna’s shares were up 4% in pre-market trading on May 4, following strong quarterly results. Shares of the company have declined 42.3% so far this year compared with the industry’s 21.4% decrease.Image Source: Zacks Investment ResearchQuarter in DetailsProduct sales, entirely from the COVID-19 vaccine, were $5.93 billion during the quarter. In the fourth quarter of 2021, product sales were $6.94 billion. The company had recorded product sales of $1.73 billion in the year-ago period.Grant revenues were $126 million compared with $194 million in the year-ago quarter. Collaboration revenues were $15 million compared with $10 million in the year-ago quarter. The company earns collaboration revenues from agreements with several big pharma/biotech companies, including AstraZeneca AZN, Merck MRK and Vertex Pharmaceuticals VRTX.Selling, general and administrative expenses were $268 million, compared with $77 million in the year-ago quarter. The significant increase was primarily due to an endowment to the Moderna Charitable Foundation along with an increase in certain commercialization costs.Research & development expenses were $554 million, up 38.2% from the year-ago period. The significant increase was primarily attributable to higher clinical costs, personnel-related cost, technology and facility-related costs, and a few others.The company ended the quarter with $19.3 billion in cash and cash equivalents, compared with $17.6 billion as of Dec 31, 2021.2022 GuidanceModerna stated that it has advance purchase agreements with different countries for Spikevax and its booster doses worth approximately $21 billion. The company believes that sales will be slightly higher in the second half of 2022 compared to the first half.The company expects R&D and SG&A expenses to be approximately $4 billion in 2022. It expects capital expenditure to be in the range of $600 million to $800 million.In February 2022, Moderna authorized a share repurchase program of $3 billion. It completed its previous share repurchase program, initiated during the third quarter of 2021, of $1 billion in January.Coronavirus Vaccine UpdateIn January, the FDA approved Moderna’s biologics license application for its COVID-19 vaccine, mRNA-1273. The company also received emergency use authorization (EUA) from the FDA for the use of its second booster dose in adults aged 50 years or older as well as in all adults with certain kinds of immunocompromise in March.The Committee for Medicinal Products for Human Use (CHMP) recommended the conditional marketing authorization for the use of Spikevax in children aged 6 to 11 years in February. In March, Canada’s government authorized the use of Spikevax in similar individuals.In April, Moderna submitted regulatory applications in the United States and Europe, seeking emergency/conditional authorization for the use of Spikevax in children aged six months to six years. The company had previously initiated filing an EUA with the FDA for the use of Spikevax in children aged 6 to 11 years.However, the authorization of mRNA-1273 for use in adolescents is pending in the United States. The authorization for the younger population is likely to happen after potential approval to the EUA request for adolescents.A phase II/III study is evaluating Moderna’s bivalent booster candidate targeting Omicron and the original COVID-19 strain. The company expects initial data from the study in June and plans to start the phase III portion later in 2022. A phase II study evaluating the Omicron-specific booster candidate is ongoing.Other Key Pipeline UpdatesModerna has several other mRNA-based pipeline candidates targeting different indications in its pipeline. The leading candidates among them are mRNA-1345 and mRNA-1647, evaluated in pivotal studies as a respiratory syncytial virus (RSV) vaccine and a cytomegalovirus (CMV) vaccine, respectively.During the first quarter, Moderna initiated a phase III study to evaluate its CMV vaccine candidate. An ongoing pivotal phase III study is evaluating the RSV vaccine candidate.The company has reported promising initial data from a phase II study evaluating its seasonal flu vaccine candidate, mRNA-1010. The company plans to start a phase III study in the Southern Hemisphere during the second quarter to evaluate the safety and immunogenicity of mRNA-1010. It may also start a late-stage study to evaluate the candidate’s efficacy during Fall 2022, if needed.The FDA has approved its investigational new drug application for its Nipah-virus vaccine candidate, mRNA-1215. A clinical study may begin soon.Menawhile, we note that Moderna has regained all rights to its mutant KRAS vaccine, mRNA-5671, from its partner, Merck. Moderna is evaluating the next steps for the program. Currently, Merck is conducting a phase I study on mRNA-5671 as monotherapy or in combination with its anti-PD 1 drug, Keytruda. Please note that Moderna continues to develop a personalized cancer vaccine candidate in collaboration with Merck.Moderna is also developing different candidates in collaboration with AstraZeneca. The candidate under the collaboration with AstraZeneca is in early- to mid-stage studies targeting oncology and cardiovascular indications. The leading candidate being developed in partnership with AstraZeneca is AZD8601 as a treatment for ischemic heart disease in a phase II study.Moderna is developing an mRNA therapeutic in collaboration with Vertex. Moderna and Vertex are developing the candidate to treat the underlying cause of cystic fibrosis. Vertex is planning to file an investigational new drug application to support the initiation of an early-stage clinical study in 2022.Moderna, Inc. Price, Consensus and EPS Surprise Moderna, Inc. price-consensus-eps-surprise-chart | Moderna, Inc. QuoteZacks RankCurrently, Moderna carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here. 5 Stocks Set to Double Each was handpicked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2021. Previous recommendations have soared +143.0%, +175.9%, +498.3% and +673.0%. Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.Today, See These 5 Potential Home Runs >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report AstraZeneca PLC (AZN): Free Stock Analysis Report Merck & Co., Inc. (MRK): Free Stock Analysis Report Vertex Pharmaceuticals Incorporated (VRTX): Free Stock Analysis Report Moderna, Inc. (MRNA): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research.....»»

Category: topSource: zacksMay 4th, 2022